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 ABSTRACT 
 
AUGMENTING THE PROTEIN C PATHWAY WITH ENDOTHELIAL TARGETED 
BIOTHERAPEUTICS: STRATEGIES TO PROMOTE PARTNERING OF TM AND EPCR 
 
Dr. Colin F. Greineder 
Dr. Vladimir R. Muzykantov 
 
The design of targeted recombinant biotherapeutics is a rapidly growing area of 
translational biomedical research, with particular relevance to acute and life-
threatening conditions, in which the available treatment options have narrow 
therapeutic indices.  Although vascular immunotargeting typically has been 
thought of as a strategy for controlling and altering pharmacokinetics, in the 
context of biotherapeutic delivery, precise localization may be the primary goal, 
allowing optimal interaction of drug with endogenous partners.  The protein C 
pathway has important protective roles in a variety of human illnesses, including 
sepsis and acute lung injury.  We recently reported a strategy for augmenting this 
pathway by anchoring thrombomodulin (TM, CD141) to the endothelium via an 
affinity ligand to platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31).  
Endothelial PECAM-1, however, is believed to localize to a different portion of the 
cell membrane than the majority of endogenous TM and its key co-factor, the 
endothelial protein C receptor (EPCR, CD201).  The current document includes 
new data indicating that recombinant TM anchored to endothelial PECAM-1 does 
not partner effectively with EPCR and describes the design, implementation, and 
validation of two strategies for more effectively replicating the enzymatic 
partnering of these two molecules.  In both cases, proximity of these co-factors 
on the surface of the endothelial membrane appears to be the key variable and 
has significant implications, affecting not only functional activity in vitro but 
therapeutic efficacy in vivo.  These findings underscore the complexity of 
targeting biotherapeutics to the plasmalemma, and suggest that precision on a 
nanometer scale is necessary for optimal biotherapeutic effect.
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CHAPTER ONE: INTRODUCTION 
 
I. A Brief review of Drug Targeting 
Over the past four decades, thousands of scientists and clinicians have 
contributed to the study of drug targeting, resulting in the development and 
testing of hundreds of strategies for the delivery of therapeutics to various 
locations in the body.  By the late 1990s, annual sales of Advanced Drug 
Delivery Systems (ADDS) in the United States exceeded $10 billion, and they 
have continued to rise rapidly1.  While a comprehensive survey of the field is 
clearly beyond the scope of this document, it is instructive to briefly review the 
origins of drug targeting and its progression from the controlled release of small 
lipophilic drugs to the precise subcellular localization of macromolecular 
biotherapeutics. 
 
Magischen Kugeln: the origins of targeted drug delivery 
With few exceptions, the pharmaceuticals in clinical use distribute 
throughout the body based on their physical characteristics (size, charge, 
lipophilicity, etc.) and the physiologic state of the patient to which they are 
administered.  Without any specific control over pharmacokinetics, most drugs do 
not accumulate at their intended site of therapeutic action.  In order to achieve 
adequate concentration at the required location, large doses, repeated 
administration, or even continuous infusion may be required, increasing the cost, 
risk of harmful side-effects, and likelihood that patients will not adhere to the 
proper regimen.  Far from theoretical, these factors lead to the failure of the 
majority of prospective therapeutics2,3, as well as millions of dollars of annual 
health care expenses related to adverse drug events and medication non-
compliance4,5.  With the development of monoclonal antibodies (mAbs) and 
advances in polymeric chemistry in the 1970s, a new field of scientific 
investigation emerged, dedicated to the development of delivery systems for the 
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controlled release, distribution, and permeation of drugs across cellular 
membranes6. 
The basic concepts of drug targeting were formulated long before any 
technology existed to apply them to biological systems.  The Nobel laureate, Paul 
Ehrlich, is largely credited with advancing the theory of Seitenketten (“side 
chains”), or cellular receptors, in the early 20th century7.  He postulated that these 
receptors were responsible for the binding of bacterial toxins to particular cells – 
e.g. the attachment of tetanospasmin to the neuromuscular junction8.  Ehrlich 
went on coin the famous term magischen Kugeln (“magic bullets”) to refer to 
therapeutics that would mimic the action of these toxins, going directly to their 
intended cellular targets and attacking diseased tissue while inflicting no harm to 
the remainder of the body9.  While Ehrlich’s vision has yet to be fully realized, 
substantial progress has been made, with the design and implementation of 
hundreds of ADDS.  Research efforts have followed a natural progression from 
relatively basic strategies of therapeutic delivery to more sophisticated 
approaches.  Each new technology has been accompanied by practical 
applications, allowing physicians and scientists to tackle increasingly difficult 
biological questions and clinical challenges10. 
 
The polymeric drug depot: the first ADDS 
Perhaps the first and most elementary therapeutic delivery system was 
that of the polymeric drug depot, a device intended for the gradual and controlled 
release of pharmaceuticals.  The earliest drug depots, such as the Norplant® 
device, consisted of non-biodegradable polymers and aimed at reducing the cost 
and complexity of treatment regimens11.  Norplant®, a series of silicone capsules 
containing the steroid hormone, levonorgestrel, produced highly effective, long-
term contraception12.  Although the device achieved notoriety in the United 
States as the subject of a number of class action lawsuits, it continues to be 
utilized in the developing world, where it has the major advantage of long-term 
efficacy without the need for consumable supplies13.  Silicone and other non-
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degradable polymers were ultimately replaced by materials such as poly(lactic-
co-glycolic) acid, or PLGA14.  Biodegradable polymers allow for repeated 
administration, and their development enabled new clinical applications, such as 
monthly dosing of gonadotropins for the treatment of endometriosis, prostate 
cancer, and children with precocious puberty15,16.  The most recent depot 
technologies have achieved actual “drug targeting”, in the sense that they 
release therapeutics at a site of disease, rather than into the systemic circulation.  
The most widely publicized and medically significant example is that of the drug-
eluting stent (DES), a polymer-coated expandable metal tube, which is deployed 
within an atherosclerotic artery as a means to maintain blood flow following 
angioplasty.  Bare metal stents, used prior to the invention of DES, were 
complicated by high rates of in-stent restenosis (ISR), a pathological process in 
which vascular smooth muscle cell proliferation, or “neointimal hyperplasia”, 
leads to vessel re-occlusion17.  DES, which slowly release immunosuppressive or 
anti-proliferative agents from their polymer coating, achieve high local 
concentrations of drug with minimal side effects and have dramatically reduced 
the incidence of ISR18–20. 
 
Mobile drug delivery systems and a focus tumor targ eting 
While polymeric depots remain the most significant achievement of the 
drug delivery field from both a medical and commercial standpoint, even the most 
sophisticated examples employ an elementary targeting strategy – i.e. the direct 
implantation of drug at its intended site of action.  Since many diseases are 
disseminated (e.g. metastatic cancer) or inaccessible to implantable depots, the 
focus of the drug delivery field has largely turned to mobile targeting systems.  
These are capable of carrying therapeutics to diseased sites throughout the 
body, where local factors stimulate release10.  The vast majority of this work has 
dealt with the delivery of inherently toxic agents, such as antimicrobials and 
antineoplastics, which are limited in their dosing and efficacy due to narrow 
therapeutic indices.  In particular, the treatment of cancer has dominated the field 
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of targeted drug delivery for nearly two decades, perhaps because of the obvious 
and intuitive appeal of delivering chemotherapeutic drugs to tumor, while sparing 
normal tissues21. 
As in other cases, the simplest strategies have been explored first, 
amongst them the passive leakage of drug carriers into tumor.  The landmark 
observation that liposomes and other nanoparticles (NPs) accumulate in 
neoplastic tissue in excess of proportional blood flow has been termed the 
“Enhanced Permeability and Retention (EPR)” effect22.  As the name implies, 
EPR is believed to be the result of a combination of phenomena.  First, NPs that 
are normally too large to cross the endothelial barrier are able to permeate 
through defective and discontinuous neovasculature, which is formed by rapidly 
growing tumors.  Second, NPs are poorly cleared from tumor interstitium due to 
impaired lymphatic drainage23.  The EPR effect has had a profound and lasting 
impact on the development of drug targeting systems, despite the fact that it only 
applies to treatment of cancer, and specifically, the targeting of solid tumors.  In 
general, priority has been placed on the development of long-circulating drug 
carriers, which maintain the high plasma concentrations needed to drive passive 
tumor targeting.   Since anti-neoplastic drugs are typically toxic, retention of drug 
carrier in the bloodstream has the added benefit of preventing access to normal 
tissues (e.g. the bone marrow), thus reducing dose-limiting side effects24. 
 
Lessons from the clinic: liposomes and early polyme r conjugates 
The most successful drug carriers – from a clinical standpoint – have been 
passively targeted liposomal formulations of small molecule chemotherapeutics.  
The prime example is that of doxorubicin, a highly effective anticancer drug, 
which unfortunately causes cumulative, dose-dependent, and irreversible 
cardiomyopathy25.  Loading doxorubicin into long-circulating polyethylene glycol 
(PEG)-coated liposomes leads to a drastic reduction in its plasma clearance rate 
(0.1L/hr vs. 45L/hr for free drug) and volume of distribution (4L as opposed to 
254L for free drug), confirming the ability of the drug carrier to limit access to 
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normal tissues26.  The first FDA approved nanoparticle, Doxil® (PEGylated 
doxorubicin liposomes) demonstrated significantly less cardiotoxicity in clinical 
trials than free doxorubicin27.  At the same time, the EPR-mediated tumor 
targeting suggested by early pharmacokinetic studies26, failed to translate into a 
marked improvement in clinical efficacy, with overall survival rates similar to 
those of free doxorubicin, depending on the type of cancer being treated and 
combination of therapies utilized27,28. 
The development of another liposomal drug, amphotericin B, is a 
remarkably similar story.  Amphotericin is a highly effective anti-fungal agent 
whose utility is limited by dose-dependent and often irreversible nephrotoxicity.   
Early studies suggested that incorporation of amphotericin into liposomes could 
prevent its interaction with mammalian cell membranes29.  Moreover, a passive 
targeting mechanism was discovered based on non-specific binding of the drug 
carrier to the fungal cell wall.  Electron microscopy revealed that amphotericin-
loaded liposomes were disrupted by this interaction and free drug released into 
the fungal cytoplasm30.  This exciting pre-clinical work led to industrial 
development and clinical testing of AmBisome (liposomal amphotericin B), which 
demonstrated significant reductions in nephrotoxicity, as compared to free drug.  
As with Doxil®, however, AmBisome has been somewhat of a disappointment in 
that the antimicrobial efficacy appears to be similar to free amphotericin31.  Given 
these relatively modest clinical results, it is not surprising that both therapeutics 
have faded from widespread use.  AmBisome has been largely eclipsed by the 
equally effective and less toxic echinocandin class of antifungals32, and Doxil® 
has been in nearly continuous nationwide shortage since going off patent in 
2009, with no generic form of the drug available25.  In February, 2013, the FDA 
approved generic doxorubicin HCl liposomes, but it remains to be seen to what 
extent the drug will regain use after this hiatus33.   
 Liposomal formulations are by no means the only ADDS available for the 
delivery of toxic, small molecule drugs.   In fact, liposomes have relatively short 
circulation times in comparison to many newer drug carriers, in part because of 
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their limited capacity for PEGylation34.  More stable carriers have been 
developed based on N-(2-hydroxypropyl)-methacrylamide (HPMA), polyglutamic 
acid (PGA), cyclodextrin, and diblock PEG/PLGA copolymers35.  The elucidation 
of endocytic pathways in the 1950s and 60s lead to an important realization by 
the Nobel laureate Christian De Duve, who suggested that the lysosome might 
be a useful target for polymeric drug carriers36.  Peptide linkers susceptible to 
lysosomal proteases, such as Gly-Phe-Leu-Gly, were used to conjugate drugs to 
HPMA, such that the resulting complex would be stable in the circulation, but 
susceptible to cleavage once the conjugate had been internalized by 
endocytosis24.  Other polymers, like PGA, are directly degraded by lysosomal 
proteases37, whereas some incorporate pH sensitive bonds to encourage 
degradation in the lysosome and release of free drug within the cell38.  A few 
classes of polymer conjugates have advanced sufficiently to reach clinical trials.  
The first, HPMA copolymer-Gly-Phe-Leu-Gly-doxorubicin, or PK1 (FCE28068), 
was tested in patients with non-small-cell lung cancer (NSCLC), colon cancer, 
and anthracycline-resistant breast cancer.  No cardiotoxicity was observed, even 
in patients receiving large cumulative doses of doxorubicin, but the drug 
produced only partial therapeutic responses, and clinical trials were not 
continued39.  The most extensive clinical testing to date has been with a PGA 
conjugate, paclitaxel poliglumex, or Xyotax.  After early trials in NSCLC were 
positive, multiple phase III trials were conducted, all of which missed their 
primary endpoint of improved survival.  Although Xyotax appears to decrease 
incidence of paclitaxel-induced side effects, this was not enough to sustain its 
clinical development37.  In general, the lesson may be that passive targeting 
strategies, while capable of reducing off-target side effects from toxic small-
molecule drugs, are not enough to produce the “magic bullets” envisioned by 
Paul Ehrlich and long-expected by the medical community. 
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Ligand-targeted therapeutics 
 The limited success of liposomal carriers and early polymer conjugates 
has turned attention to the development of more sophisticated targeting 
strategies.  In particular drug carriers have been decorated with nutrients, peptide 
hormones, antibodies, and other molecules designed to promote binding and 
uptake by target cells.  The renewed interest in ligand targeting is not entirely 
surprising, given the recent commercial success of monoclonal antibody (mAb) 
therapeutics.  One of the most successful examples has been that of folate 
targeting.  While folic acid is essential for proliferation of all mammalian cells, 
only a few cell types, amongst them cancer cells, express high affinity folate 
receptors (FRs)40.  A variety of potent anti-cancer drugs have been generated by 
conjugation of toxic agents to folate.  These conjugates bind FRs and are 
internalized.  In some cases, such as the pseudomonas exotoxin PE38, the 
cargo has a built-in mechanism of endosomal escape41.  In other cases, 
conjugates have been designed with disulfide linkages, resulting in the discharge 
of free drug in the reducing environment of the endosome42.  Most importantly, 
the development of folate-targeted therapeutics has been accompanied by 
cognate imaging agents, which allow for the identification and selection of 
patients whose tumors overexpress FRs.  The pairing of molecular imaging and 
targeted drug delivery is a powerful concept, which has led to unprecedented 
success and multiple ongoing clinical trials43. 
 
New priorities: the emergence of macromolecular bio therapeutics 
 Perhaps the most significant shift in the field of drug targeting is the one 
currently underway, which has been driven by the rapid growth of a new class of 
drugs, macromolecular biotherapeutics.  In the thirty years since the FDA 
approval of recombinant human insulin, biotherapeutics (also referred to as 
“biologics”) have become a major force in the pharmaceutical industry44.  This 
rapidly growing category now accounts for 5 of the top 10 best-selling drugs and 
more than 50% of the portfolio of most pharmaceutical companies45.  The most 
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successful examples have been recombinant proteins that boost natural 
protective mechanisms, which are deficient or defunct in human disease.  
Examples include erythropoietin (EPO) administered to boost red cell production 
in patients with chronic renal failure and granulocyte colony-stimulating factor (G-
CSF) used to combat chemotherapy-induced neutropenia46.  While both EPO 
and G-CSF have achieved widespread use and commercial success47, they 
represent a relatively small subset of biotherapeutics that require no site-specific 
delivery.  Like small molecule drugs, most macromolecules (one notable 
exception being mAbs) do not inherently accumulate at their intended site of 
therapeutic action.  If anything, the size, complexity, and biocompatibility of these 
drugs limits their ability to permeate cell membranes and makes them more 
susceptible to the body’s mechanisms of inactivation and elimination48.  
Moreover, the greatest advantage of biotherapeutics – their extreme specificity 
for particular endogenous biological pathways – also represents one of their 
greatest challenges, in that these agents require precise delivery to specific 
locations in order to exert optimal activity. 
A good example is that of small interfering ribonucleic acids (siRNA), 
which are, in principle, able to reversibly silence the expression of any gene of 
interest.  siRNA could become the most important class of therapeutics in history, 
with the capacity to modulate the pathogenesis of nearly any disease.  However, 
they must be delivered to a specific multiprotein complex, the RNA-induced 
silencing complex (RISC), in order to have an effect.  Numerous obstacles stand 
between siRNA and the RISC, including RNAse-mediated destruction, immune 
recognition and clearance, lack of tissue targeting, inefficient cellular uptake, and 
inability to escape endosomal compartments and reach the perinuclear region of 
the cytoplasm49.  As a result, most of the RNA therapeutics in early clinical trials 
either require direct application of genetic material to the organ of interest (e.g. 
intravitreal injection) or target the liver via lipid nanoparticles naturally taken up 
through the fenestrated endothelium50. 
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Another interesting example is that of fibrinolytic enzymes.  Nearly two 
decades after the landmark 1995 NINDS trial51, which demonstrated a long-term 
benefit of recombinant tissue plasminogen activator (t-PA) in the setting of acute 
ischemic stroke, less than 5% of stroke patients receive fibrinolytic therapy52.  
The strict eligibility criteria, which exclude the vast majority of patients, are the 
result of a narrow therapeutic window and potentially life-threatening toxicity, 
intracranial hemorrhage53.  As is often the case, poor pharmacokinetics resulting 
from extremely rapid clearance (the plasma half-life of free t-PA is approximately 
3-1/2 minutes)54 and the presence of a circulating inhibitor55, necessitate large 
bolus doses and continuous infusion in order to achieve effective thrombolysis.  
This increases the cost and risk of side effects and has severely limited clinical 
use.  A variety of efforts have been made to alter pharmacokinetics and protect 
the drug en route to its therapeutic site, including PEGylation of the enzyme, 
genetic modification, and encapsulation in a variety of liposomal and polymeric 
drug carriers34.  While these modifications have improved circulation time, many 
simultaneously impede clot permeation and accessibility to fibrin.  
Correspondingly, none of these approaches have proven to have a decisive 
advantage over t-PA in the treatment of acute stroke56. 
The general lesson appears to be that targeting of macromolecular 
biotherapeutics may be quite different from the delivery of inherently toxic, small 
molecule drugs, especially in applications unrelated to cancer.  Characteristics 
which may be ideal for an ADDS carrying doxorubicin or paclitaxel, such as 
prolonged circulation time and impaired entry into normal tissues, may be 
disadvantageous in the delivery of biotherapeutics.  Attachment to targeting 
ligands, polymers, or stealth agents (e.g. PEG) may impair access to the 
necessary site of action or block partnering with cofactors.  Until technology is 
developed to precisely localize biotherapeutics and optimize their interaction with 
endogenous partners, the clinical development of numerous candidate drugs will 
be stifled, and the translation of many scientific discoveries will remain 
impossible. 
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II. Developing Therapeutics for Acute Vascular Diso rders 
 The obstacles encountered in the development and clinical testing of 
recombinant fibrinolytics demonstrate the enormous challenges which face the 
scientific and medical community in designing therapeutics for the treatment of 
acute vascular disorders.  Cardiovascular disease is already the most common 
cause of death in industrialized nations, and its incidence is on the rise57.   The 
acute manifestations are typically unforeseeable and life-threatening, meaning 
that candidate therapeutics must work after the onset of symptoms, achieve rapid 
efficacy, and demonstrate limited off-target side effects.  The most severe 
vascular disorders, including sepsis, acute lung injury, and post-traumatic multi-
organ failure, have been labeled “critical illnesses”, owing to the lack of disease-
specific therapies and reliance on sophisticated supportive measures in treating 
afflicted patients58.  Despite substantial improvements in emergency and 
intensive care, the morbidity and mortality of these conditions has remained 
essentially unchanged59,60. 
 
Endothelial cells: a critical target 
 The vascular endothelium, once thought to be a passive barrier between 
blood and tissue, is now recognized to have an important role in many of these 
same diseases in which the medical field has struggled to achieve improved 
outcomes61–63.  Endothelial cells (ECs) project a variety of protein complexes into 
the vascular lumen, which interact with circulating blood components and allow 
ECs to sense and respond to changes in flow, coagulation, nutrient delivery, and 
inflammation64,65.  In the last several decades, scientists have elucidated a 
variety of endothelial mechanisms, which help to maintain blood fluidity, control 
vascular tone and permeability, and regulate the innate immune response66.  
Advances in tissue culture have allowed the study of these mechanisms not only 
at rest, but under different patterns of flow67.  Molecular biology has enabled the 
identification of many of the proteins involved in these protective pathways, as 
well as variations in their level of expression in segments of the vasculature 
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exposed to high or low shear stress.  Finally, the creation of endothelial-specific 
genetic modifications in animals and the identification of disease-linked 
polymorphisms in patients have provided insight into the relative importance of 
these endothelial pathways in human disease68–70. 
 Despite the enormous accumulation of knowledge regarding endothelial 
biology, physicians and scientists remain largely unable to influence the 
endothelial mechanisms known to play a part in acute vascular disorders in 
humans.  Only a small number of drugs have significant effects on ECs and 
those that do typically have little endothelial specificity (e.g. non-steroidal anti-
inflammatory drugs), require complex regimens of administration (e.g. 
epoprostenol)71, or are meant for the treatment of chronic conditions like 
systemic hypertension (e.g. angiotensin converting enzyme-inhibitors).  
Biotherapeutics, in particular, tend to have no innate affinity for the endothelium, 
and only a tiny fraction of administered dose is typically retained at the vascular 
margin.  While the field of drug targeting has begun to take an interest in 
endothelial delivery, efforts have focused on directing therapeutics to tumor-
associated neovasculature72.  Only a small number of investigators have 
prioritized the delivery of biotherapeutics to normal ECs, and limited capacity 
exists to target specific vascular beds or areas of endothelial activation73–76. 
 
The Protein C pathway and its role in acute vascula r disease 
 Amongst the endogenous endothelial systems considered for 
pharmacologic intervention, the protein C pathway has attracted perhaps the 
most intense interest, in part because of its involvement in the coagulation 
cascade, the innate immune response, and the control of vascular permeability77.  
The existence of protein C (PC) was first predicted in 1970 by Ewa Marciniak, 
who described a “coagulation inhibitor elicited by thrombin”78.  In 1976, this factor 
was identified as vitamin K dependent and named “protein C” by Johan Stenflo, 
because it was present in the third major peak eluted off of an anion exchange 
column following the barium citrate adsorption of bovine plasma79.  Like other 
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vitamin K-activated, gamma-carboxyglutamate (Gla) containing factors, PC was 
found to be a zymogen, cleavable by thrombin and Russell’s viper venom80.  
Unlike other coagulation zymogens, however, the majority of PC could be 
recovered in serum81.  Indeed, its slow rate of activation in clotting assays led 
Charles Esmon to search for an endothelial cofactor capable of accelerating the 
generation of activated protein C (APC).  By perfusing discarded pig’s ears 
(collected from a local slaughterhouse) with thrombin and PC, Esmon discovered 
that such a cofactor was present, and subsequent efforts led to the isolation of 
thrombomodulin (TM)82. 
 TM was ultimately characterized as an endothelial transmembrane 
glycoprotein capable of altering the enzymatic specificity of thrombin.  When 
bound to TM, thrombin no longer activates fibrinogen, Factor V, or platelets, but 
instead generates APC83.  Although it is often thought of as an anticoagulant, TM 
differs substantially from molecules like antithrombin, heparin, hirudin, and the 
new direct thrombin inhibitors (e.g. dabigatran).  Rather than simply inhibiting 
thrombin activity, TM couples it to the generation of APC, which has anti-
inflammatory, anti-apoptotic, and endothelial barrier stabilizing activity, in addition 
to anticoagulant functions.  The importance of the protein C pathway is 
demonstrated by the uniform lethality of homozygous protein C deficiency, which 
manifests as neonatal purpura fulminans84.  No genetic form of human TM 
deficiency exists, presumably due to embryonic lethality.  In fact, even mice 
homozygous for a single point mutation in TM, which disrupts thrombin binding, 
have a severe prothrombotic and hyperinflammatory phenotype85. 
 The role of the protein C pathway in maintaining homeostasis is also 
demonstrated, albeit in less absolute terms, by the nearly universal finding of 
endothelial TM deficiency in the presence of human vascular disease.  Loss of 
TM has been demonstrated in nearly every condition involving acute or chronic 
vascular inflammation, from sepsis and ischemia/reperfusion injury to 
atherosclerosis and diabetic neuropathy86–89.  In addition to transcriptional 
downregulation, there is evidence to suggest that TM is internalized, inactivated, 
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and cleaved from the endothelial membrane in these conditions.  A wide variety 
of mediators have been implicated, including cytokines, reactive oxygen species, 
and neutrophil-derived proteases90–93.  Given its pervasive nature, it seems likely 
that this process must have conferred a selective advantage in some 
evolutionary situations, such as localized infection or trauma.  In the context of 
contemporary human medicine, however, loss of endothelial TM is no longer 
advantageous and has become an important component of the pathogenesis of 
numerous vascular diseases. 
 In addition to TM and PC, a third molecule, the endothelial protein C 
receptor (EPCR), has a critical role in the protective functions of this system.  
APC generation by the TM/thrombin complex is accelerated between 5 and 20 
fold when PC is bound to EPCR, depending on whether measurements are 
made in vitro or in vivo94,95.  Moreover, EPCR appears to play a central role in 
mediating the anti-inflammatory, anti-apoptotic, and barrier stabilizing effects of 
APC84.  Although EPCR has a short cytoplasmic tail and no direct intracellular 
signaling activity, it co-localizes with the protease-activated receptor 1 (PAR1) in 
caveolin-1 rich microdomains and participates in its activation by APC96.  
Specifically, APC must be bound to EPCR to cleave PAR197.  Some in vitro 
experiments indicate a second mechanism of protective signaling through PAR1, 
in which the specificity of thrombin is altered when EPCR is occupied by PC, 
switching it from a pro-inflammatory to anti-inflammatory signal98.  The 
APC/EPCR complex also appears to signal through additional receptors, 
including the sphingosine-1-phosphate receptor (S1PR) and PAR399–101.  Like 
TM, EPCR is cleaved from the endothelial membrane in the presence of 
systemic inflammation.  Plasma levels of a soluble form of EPCR (sEPCR) are 
elevated in human sepsis and a variety of autoimmune disorders and correlate 
with the severity of underlying disease102–104.  In vitro studies indicate that a 
matrix metalloprotease is responsible for EPCR cleavage and that release of 
sEPCR is stimulated by inflammatory mediators, reactive oxygen species, and 
coagulation factors105. 
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 Studies with genetically modified mice have confirmed the role of EPCR in 
mediating protective effects of the protein C pathway in vivo.  These results are 
particularly significant because of the distinct tissue distribution of TM and EPCR, 
the former predominantly found on capillaries and smaller vessels and the latter 
with higher expression on large vessels106.  These differing patterns of 
expression have led to questions about the importance of EPCR and its 
partnering with TM in vivo.  Nonetheless, EPCR is clearly involved in mediating 
protective effects, based on observations that mice with genetically-induced 
EPCR deficiency (~10% of normal expression levels) are more susceptible to 
endotoxemia than wild type controls, whereas animals with endothelial-specific 
overexpression of EPCR (150 times normal expression levels) are markedly 
more resistant69,107.  One theory is that the level of colocalization of TM, EPCR, 
and PAR1 might vary depending on the vascular bed examined, and that this 
might explain the overall importance of this signaling pathway, despite distinct 
patterns of expression noted in some organs84.  Consistent with this idea, one 
recent study investigated the importance of EPCR in maintaining endothelial 
barrier function in various organs and found significant variation depending on 
the vascular bed involved108.  Figure 1.1 shows the major components of the 
Protein C Pathway, in schematic form, and their primary functions at the luminal 
endothelial cell membrane.  
 
III. Biotherapeutic Interventions into the Protein C Pathway 
 Multiple approaches have been proposed to reverse the pathogenic 
suppression of the protein C pathway, including endothelial gene therapy and the 
infusion of recombinant proteins.  The former approach has intuitive appeal and 
has provided proof-of-principle for replenishing endothelial TM109–111, and 
potentially EPCR as well.  Nonetheless, it requires the site-specific delivery of 
siRNA or other genetic material – not only to endothelial cells, but a specific 
compartment of the EC cytoplasm.  As alluded to above, significant technological 
limitations exist which make gene therapy unrealistic, except in rare clinical 
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contexts (e.g. ex vivo viral transduction of ECs in harvested vein segments prior 
to bypass grafting)112.  Even if the technical limitations are overlooked, temporal 
considerations are unlikely to permit this approach in the treatment of emergent 
conditions like sepsis, stroke, and acute lung injury. 
 
Xigris® and other recombinant proteins 
In 1987, Taylor and Esmon reported that recombinant human APC (rhAPC) 
protected baboons from an otherwise lethal infusion of bacteria113.  The timing of 
this discovery was fortuitous, coinciding not only with the emergence of 
biotherapeutics as a viable class of pharmaceuticals, but also the recognition of 
systemic inflammation and derangements in coagulation as important 
components of human sepsis114.  rhAPC was developed by the pharmaceutical 
industry and became one of a number of recombinant proteins tested in septic 
patients in the late 1990s.  Ultimately, the phase III PROWESS trial 
demonstrated a survival benefit in patients randomized to rhAPC (28-day 
mortality of 24.7% vs. 30.8% with placebo), and led to the FDA approval of 
drotrecogin alfa (rhAPC), or Xigris®115.  Unfortunately, as in the case of 
recombinant t-PA, poor pharmacokinetics severely limited its clinical utility.  In 
fact, the similarities to t-PA are striking: rhAPC is rapidly cleared (the plasma 
half-life of free APC is approximately 13 minutes)116 and inactivated by a 
circulating inhibitor, and these factors led to the decision to administer the drug 
via continuous infusion.  This in turn increased the cost and risk of life-
threatening hemorrhage, and ultimately, the drug was withdrawn from the market 
when its risks were shown to outweigh any potential benefit117. 
 A variety of efforts have been made to replicate the beneficial 
effects seen with rhAPC, while avoiding its negative characteristics.  Genetically 
modified forms have been created which demonstrate reduced inactivation of 
Factors Va and VIIIa118.  These mutants lack the anti-coagulant and pro- 
fibrinolytic effects of wild type APC, while preserving other beneficial activities.  In 
fact, the lack of anti-coagulant effect actually results in indirect anti-inflammatory 
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Figure 1.1. The Protein C Pathway 
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actions not seen with rhAPC, due to the increased generation of thrombin and 
activation of the thrombin-activatable fibrinolysis inhibitor (TAFI).  In addition to 
blocking the efficient activation of plasmin, TAFI inhibits bradykinin and the 
anaphylatoxins C3a and C5a119, both of which contribute to the systemic 
inflammatory response.  Although these genetic modifications may address some 
of the limitations of rhAPC120, the modified drugs still face significant 
pharmacokinetic challenges and their ability to succeed in the clinical realm has 
yet to be determined. 
Another strategy for augmenting the protein C pathway is the infusion of 
soluble forms of TM.  Unlike infusion of an activated zymogen, soluble TM (sTM) 
reproduces some of the “on demand” nature of the endogenous protein C 
pathway, generating a biological effect primarily at sites of thrombin 
generation121.  Genetic modifications have been made to sTM to separate the 
function of its domains, prolong circulation time, and prevent inactivation by 
reactive oxidant species93,122,123.  While preliminary studies in animal models and 
early stage human clinical trials have demonstrated beneficial effects124–126, sTM 
and its derivatives fail to reproduce a key aspect of the protein C pathway, its 
localization to the endothelial membrane.  Although improper localization in this 
case may not be as significant as it is with siRNA or other biotherapeutics, it does 
prevent the interaction of recombinant TM with a key cofactor, the endothelial 
protein C receptor (EPCR). 
 
Endothelial targeted biotherapeutics  
 Endothelial targeting of recombinant TM was first reported by our 
laboratory in 2008127.  To anchor sTM to the luminal membrane, its natural 
location and (presumably) site of optimal activity, it was fused to a PECAM-1-
specific single chain antibody fragment, 390 scFv.  The 390 scFv/TM fusion 
protein was found to bind to immobilized PECAM-1 in vitro and to lung ECs 
following IV injection.  Mice treated with 390 scFv/TM were protected from both 
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ischemic and inflammatory lung injury, without the bleeding side effects seen with 
equipotent doses of recombinant mouse APC127. 
 While the ability of endothelial-anchored 390 scFv/TM to partner with 
endogenous EPCR was not tested in these initial experiments, studies conducted 
in the field of biomaterials suggested that this would be an important question.  
Material scientists have long taken an interest in the protein C pathway as a 
potential means of preventing the activation of the immune system and 
coagulation cascade on implantable medical devices128.  TM has been 
immobilized on polyurethane, PEG-modified glass, and even liposomes129–131.  In 
2006, one group reported in vitro flow studies utilizing a membrane-mimetic 
material, which had been functionalized with phospholipids and TM.  The rate of 
APC generation was measured following the perfusion of thrombin and PC.  At 
relatively low TM surface density, increases in TM surface content accelerated 
APC production.  Beyond a certain critical TM density, however, a plateau was 
reached and further increases in TM surface content had no effect132.  This 
finding was attributed to a limitation in protein C availability at the surface, 
presumably due to the absence of EPCR.  Subsequent efforts achieved higher 
rates of APC generation via co-immobilization of TM and EPCR, but the effect 
was only seen if the recombinant proteins were in close proximity (< 10nm).  
Random, unordered distribution of TM and EPCR was not effective133.  This 
potentially stringent requirement for proximity between TM and EPCR gave rise 
to several important questions regarding the potential partnering of EC-anchored 
390 scFv/TM and endogenous EPCR. 
 
IV. Scope of the Dissertation 
 As indicated above, the primary goal of targeting recombinant TM to the 
endothelial membrane has been to optimize its activity by allowing for partnering 
with endogenous cofactors.  As of 2009, it remained unknown to what extent 390 
scFv/TM was able to take advantage of its localization.  There were three 
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questions, in particular, which we wanted to answer, and which form the basis of 
this dissertation: 
 
1) Is thrombin bound to membrane-anchored scFv/TM capable of interacting 
with PC bound to EPCR? 
 
 There were two reasons for concern that partnering between scFv/TM and 
EPCR might not be possible.  The first was related to the design of the 390 
scFv/TM fusion protein, which was constructed with the scFv moiety on the N-
terminal end and the sTM moiety on the C-terminal end (figure 1.2a).  While this 
design was chosen for technical reasons (prior data suggested that 390 scFv 
may not bind to PECAM-1 if a large cargo protein like TM was fused to its N-
terminus), it left the sTM moiety in an “inverted” conformation.  The N-terminal 
lectin domain of TM is typically the most distal to the membrane, with the six 
EGF-like domains, including the thrombin-binding site (EGF-like domains 5 and 
6), more proximal.  In contrast, the lectin domain in the fusion is adjacent to the 
scFv and the EGF domains may be further from the membrane, depending on 
the exact conformation the protein takes after binding to PECAM-1 (figure 1.2b). 
 The second, and somewhat related, reason for concern was that the 
combination of the scFv moiety and PECAM-1 might introduce too much distance 
between recombinant TM and the surface membrane to allow access to PC and  
EPCR (Figure 1.2b).  Some separation from the plasmalemma is known to be 
required for full activity of the thrombin/TM complex, which sits approximately 
65Å from the cell surface134.  Specifically, this was studied in a series of 
experiments, in which the Ser/Thr rich region of TM (which is positioned 
immediately adjacent to the membrane) was replaced by polypeptides of varying 
length.  Decreasing the size of this spacer progressively diminished thrombin 
binding and protein C activation, suggesting that the active site is optimally held 
at a certain distance from the membrane135.  Nonetheless, the interposition of 
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PECAM-1 and the 390 scFv might introduce a significantly greater distance than 
65Å, and the effect of this displacement on partnering with EPCR was unknown. 
 
2) Assuming the thrombin-scFv/TM complex is physically capable of interacting 
with PC-EPCR, do differences in the distribution of PECAM-1 and EPCR 
along the EC membrane prevent effective enzymatic partnering? 
 
PECAM-1 on ECs is predominantly localized to cell-cell junctions136,137, whereas 
endogenous TM and EPCR are believed to be concentrated in lipid rafts in the 
endothelial apical plasmalemma96,138.  Based the results of the previously 
described experiments involving co-immobilization of TM and EPCR on artificial 
surfaces, there was concern that PECAM-anchored TM might have insufficient 
proximity to allow effective partnering with EPCR (figure 1.2b). 
 Chapter 2 details our experimental approach to these first two questions.  
We describe an assay for measuring the activation of PC by cell membrane-
bound TM fusion proteins.  We use this method to show that 390 scFv/TM is 
capable of partnering with EPCR, at least while anchored to the membrane of 
non-endothelial cells, engineered to overexpress mouse PECAM-1 and EPCR.  
In contrast, experiments on mouse ECs indicate that PECAM-anchored 390 
scFv/TM is largely unable to partner with EPCR, at least in comparison to 
endogenous TM. 
 
3) What approaches can be designed to allow or improve enzymatic partnering 
between EC-anchored scFv/TM and EPCR (without compromising 
therapeutic delivery)? 
 
In the light of the results presented in Chapter 2, two strategies were developed 
for enhancing enzymatic partnering between endothelial-targeted TM and EPCR.  
The implementation and validation of these approaches are discussed at length 
in Chapters 3 and 4. 
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CHAPTER TWO: PECAM-BOUND scFv/TM – MEASUREMENT OF    
PROTEIN C ACTIVATION AND PARTERING WITH EPCR 
 
 
I. INTRODUCTION 
As discussed in Chapter 1, vascular immunotargeting of drugs involves 
conjugation or recombinant fusion to specific affinity ligands of determinants on 
the luminal surface of ECs.  Although in the past it has been thought of as a 
strategy for controlling and altering pharmacokinetics, its application to 
biotherapeutics is primarily intended to precisely localize drugs and allow optimal 
interaction with endogenous partners.  Indeed, the primary justification for 
targeting recombinant TM to ECs, reported by our lab in 2008, was not one of 
pharmacokinetics127.  Other means exist for achieving prolonged circulation of 
sTM, including subcutaneous injection, chemical modification (e.g. PEGylation), 
genetic alteration (e.g. solulin), and attachment to blood cells139–141.  While these 
therapeutics are systemic and cannot be directed to one organ in particular, the 
fact that sTM activates PC only at sites of thrombin generation “localizes” its 
effect to sites of inflammation or thrombosis. 
Given that endothelial targeting of TM was primarily motivated by potential 
partnering with EPCR and other endogenous cofactors, our group had great 
interest in determining if such interaction was possible.  To address these 
questions, we developed an assay for measuring the activation of protein C by 
cell-bound 390 scFv/TM and utilized this method to determine the extent of 
partnering with EPCR. 
 
II. RESULTS 
 
Studies on Non-Endothelial REN Cells 
The human mesothelioma cell line REN is a useful model system, with no 
expression of mouse PECAM, ICAM, TM, or EPCR at baseline.  REN-PECAM 
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Figure 2.1. Non-endothelial REN cell system 
Western blot demonstrating expression of mouse endothelial proteins on REN 
cells (wt = wild type) and stably transfected REN-PECAM cells, with MS1 mouse 
endothelial cells included for comparison. 
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cells, which stably express mouse PECAM-1, have been utilized in our laboratory 
extensively (Figure 2.1)142,143. 
 
Binding and functional activity of 390 scFv/TM on PECAM-expressing REN cells 
Both 390 scFv and 390 scFv/TM fusion protein demonstrated nanomolar affinity 
to REN-PECAM cells.  Little or no non-specific binding was seen to wild type 
REN cells (Figure 2.2a,b).  For the next series of experiments, we developed an 
assay for measuring the activation of protein C by TM fusion proteins bound to 
the surface of REN cells.  390 scFv/TM demonstrated dose-dependent, 
thrombin-mediated activation of protein C on REN-PECAM cells, but not on wild 
type REN cells (Figure 2.3).  Recombinant sTM was used as an additional 
control and showed no activity on either cell type. 
 
EPCR expression potentiates the functional activity of 390 scFv/TM bound to 
REN-PECAM cells 
 Having determined the baseline rate of protein C activation by REN cell-
bound 390 scFv/TM, we next assessed its ability to partner with EPCR in the 
membrane.  To achieve this, EPCR expression was induced on REN-PECAM 
cells, producing the stable cell line REN-PECAM-EPCR.  Expression of EPCR 
was confirmed by western blotting (Figure 2.4).  Expression of EPCR expression 
resulted in ~4-fold enhancement of thrombin-mediated APC generation by 390 
scFv/TM (Figure 2.5a).  To confirm that this effect was dependent on EPCR, we 
utilized a monoclonal antibody that blocks the binding of PC to murine EPCR and 
thereby inhibits its ability to accelerate APC production by the thrombin-TM 
complex69.  Treatment with this antibody resulted in approximately 75% reduction 
in APC generation (Figure 2.5b). 
 
Studies on Mouse Endothelial Cells 
EPCR expression on MS1 cells vs. REN-PECAM-EPCR cells 
 While transfected REN cells are convenient for studying TM fusion  
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Figure 2.2. Binding of 390 scFv and scFv/TM to REN- PECAM cells 
Cell based ELISAs show binding of (a) 390 scFv and  (b) 390 scFv/TM fusion 
protein to PECAM expressing REN cells.  No significant binding is seen to wild 
type REN cells.  Experiments were done in triplicate (each point shown 
represents three wells).  SD are shown but too small to be seen in most cases.  
EC50 is shown for each curve. 
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Figure 2.3. APC generation by 390 scFv/TM on REN-PE CAM cells 
390 scFv/TM activates protein C while bound to PECAM-expressing cells. 
Minimal APC is generated on wild type REN cells, presumably due to lack of 
binding. All experiments were done in triplicate.  Data shown are mean ± SD. 
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Figure 2.4. Creation of REN cells stably expressing  PECAM and EPCR 
Western blot of REN-PECAM-EPCR cells, which stably overexpress mouse 
EPCR.  REN wt, REN-PECAM, and MS1 endothelial cells included as 
comparison. 
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Figure 2.5. APC generation by 390 scFv/TM on REN-PE CAM-EPCR vs. 
REN-PECAM cells 
(a) A ~4-fold increase in APC generation is seen when 390 scFv/TM is anchored 
to REN-PECAM-EPCR cells, as compared to EPCR-negative counterparts.  
Differences between groups were highly significant (p < 0.001) at all (non-zero) 
doses of 390 scFv/TM fusion protein. (b) Cells treated with anti-EPCR mAb1560, 
which blocks protein C binding to EPCR, show ~75% reduction in APC 
generation. Differences between groups were highly significant (p < 0.001) at all 
(non-zero) doses of fusion protein.  All experiments were done in triplicate.  Data 
shown are mean ± SD, error bars too small to be seen at some points. 
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proteins, they clearly represent an artificial system, in which the surface 
expression and distribution of PECAM, ICAM, and EPCR do not necessarily 
reflect what is present on endothelial cells.  For example, radioimmunoassays 
performed using 125I-labeled anti-EPCR revealed that the number of binding sites 
on REN-PECAM-EPCR cells is an order of magnitude higher than on MS1 
mouse endothelial cells (Figure 2.6). 
 
Binding of 390 scFv/TM to MS1 endothelial cells 
 390 scFv/TM demonstrated specific binding to PECAM-1, as evidenced by 
near complete inhibition of binding by a 10-fold excess of parental 390 mAb 
(Figure 2.7).  Calculated affinity constants were similar to those seen in previous 
experiments using REN-PECAM cells. 
 
Suppression of endogenous TM on MS1 cells 
 Measuring the activity of 390 scFv/TM while bound to MS1 cells proved to 
be substantially more complicated than on REN cells, due to high level of 
expression of endogenous TM.  These cells express endogenous TM at high 
level in a stable fashion resistant to agents that typically suppress its level in 
endothelium (e.g., TNF and other cytokines).  To measure fusion protein-
specific APC generation on endothelial cells, we experimented with several 
methods of suppressing the activity of endogenous TM.  The first of these 
methods utilized mouse TM-specific siRNA.  Although western blotting 
demonstrated robust suppression of TM levels, relatively high levels of lipid 
transfecting reagent were required (Figure 2.8a).  The cells were damaged in this 
process and inevitably lifted off gelatinized 24 well plates during the repeated 
washes of the APC generation assay.  We subsequently transfected MS1 cells 
with a TM-specific shRNA vector containing the puromycin resistance gene.  
Stably transfected cells were selected and maintained in puromycin.  
Unfortunately, western blotting demonstrated no difference in the expression of 
mouse TM in shRNA-transfected vs. wild type cells (Figure 2.8b). 
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Figure 2.6. Quantification of EPCR on ECs vs. REN-P ECAM-EPCR cells 
(a) Radioimmunoassays of 125I-labeled anti-EPCR antibody (mAb1560). 
(b) Summary of anti-EPCR binding parameters on each cell type.  
Radioimmunoassays were done in quadruplicate (i.e. each data point represents 
4 wells of cells).  Data shown are mean ± SD. 
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Figure 2.7. Binding of 390 scFv/TM to MS1 mouse ECs  
Specificity is demonstrated by inhibition of binding by 10-fold excess of parental 
390 mAb. All experiments were done in triplicate (i.e. each data point represents 
3 wells of cells).  Data shown are mean ± SD, error bars too small to be seen at 
some points. 
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Figure 2.8. Attempts to knockdown endogenous TM on MS1 cells 
(a) Mouse TM specific siRNA effectively suppressed TM, especially at high 
doses.  Unfortunately, cell toxicity made APC generation assays technically 
impossible.  (b) Stable transfection of a mouse TM specific shRNA did not result 
in effective knockdown, despite antibiotic selection. 
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Isolation of lung microvascular endothelial cells from TMpro/pro mice 
 TMpro/pro mice are homozygous for a single amino acid mutation, 
Glu404Pro, in the interdomain loop between the fourth and fifth EGF-like 
domains of TM.  This mutation results in a 75% reduction in the level of 
expression of TM in lung homogenates, a ~100-fold reduction in thrombin 
binding, and a ~1000-fold reduction in the rate of APC generation144.  We 
reasoned that TMpro/pro ECs would provide an ideal system for testing activation of 
protein C by EC-bound 390 scFv/TM.  Accordingly, lung endothelial cells were 
isolated from TMpro/pro mice.  The cells were grown to passage 4 (Figure 2.9a) 
and tested for the binding of 390 scFv/TM.  Unfortunately, no binding was seen 
on TMpro/pro ECs, in contrast to MS1 cells (Figure 2.9b). 
 
Blockade of endogenous TM on MS1 cells 
 Another strategy employed to suppress the activity of endogenous TM 
was that of antibody blockade.  A variety of anti-mouse TM (mTM) antibodies 
were screened for their ability to block thrombin binding and APC generation, 
with PPACK-inactivated thrombin used as a positive control.  While several anti-
mTM mAbs had no effect, a polyclonal anti-mTM antibody was able to fully inhibit 
APC generation (Figure 2.10a).  Unlike PPACK-thrombin, the polyclonal antibody 
had a sustained effect after washing (Figure 2.10b).  Sustained blockade of 60-
70% of endogenous TM activity, provided by anti-TM antibody, enabled 
measurement of dose responsive, 390 scFv/TM-dependent protein C activation 
(Figure 2.10c). 
 
Functional activity of EC-bound 390 scFv/TM and lack of EPCR partnering 
 We employed anti-mTM antibody blockade to assess protein C activation 
by 390 scFv/TM anchored to MS1 cells.  Since the expression of PECAM-1 on 
ECs is more than an order of magnitude higher than that of TM (106 copies/cell 
vs. 4x104 copies/cell)145,146, we expected that saturating concentrations of 390 
scFv/TM (e.g. 40nM based on enzyme-linked Immunosorbent assays, ELISAs)  
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Figure 2.9. Isolation and culture of lung ECs from TMpro/pro  mice  
(a) Phase contrast image of isolated ECs.  (b) Cell-based ELISA demonstrated 
binding of 390 scFv/TM to MS1 cells, but not isolated TMpro/pro cells. 
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Figure 2.10. APC generation on MS1 cells following blockade of 
endogenous TM 
(a) Blockade of endogenous TM with PPACK-inactivated thrombin and polyclonal 
anti-TM prevents thrombin-dependent APC generation.  Monoclonal anti-TM 
antibodies, clone 411 and clone 273 (generously provided by Dr. Stephen J. 
Kennel, University of Tennessee, Knoxville, TN) did not inhibit APC generation. 
(b) Antibody blockade, but not inactivated IIa, had a sustained blocking effect 
when cells were washed prior to addition of thrombin and protein C. (c) Antibody 
blockade of endogenous TM enabled measurement of dose responsive, fusion 
protein-dependent protein C activation. All experiments were done in triplicate.  
Data shown are mean ± SD, error bars too small to be seen at some points. 
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Figure 2.11. APC generation by 390 scFv/TM on MS1 c ells 
MS1 cells blocked with anti-mTM antibody and treated with 390 scFv/TM 
unexpectedly showed less activation of PC than unblocked MS1 cells (which 
reflect the activity of endogenous TM).  One potential explanation is the finding 
that APC generation by 390 scFv/TM is not significantly affected by blockade of 
EPCR (p = 0.32), unlike unblocked MS1 cells (p << 0.001), indicating ineffective 
partnering of the fusion protein with this key co-factor.  Experiments were done in 
triplicate (i.e. n=3).  Data shown are mean ± SD. 
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would result in substantially higher levels of APC than unblocked MS1 cells.  
When we compared unblocked MS1 cells to antibody-blocked cells treated with 
40nM of 390 scFv/TM, however, we found that the latter actually generated 
significantly less APC (Figure 2.11). 
 To assess the role of EPCR in this result, we utilized EPCR blocking 
antibody and found that treatment of MS1 cells with the anti-EPCR antibody 
resulted in approximately 50% reduction in thrombin-dependent activation of 
protein C by endogenous TM.  In contrast, there was no significant effect on the 
activation of protein C by 390 scFv/TM (Figure 2.11). 
 
III. CONCLUSIONS 
 Several significant conclusions can be drawn from the in vitro data 
presented in this chapter.  First, experiments using the non-endothelial REN 
cell system clearly demonstrate that partnering between TM fusion proteins 
and EPCR is at least possible.  In this system, in which EPCR is marked 
overexpressed (~10-fold more copies per REN-PECAM-EPCR cell than MS1 
cell), PECAM-anchored 390 scFv/TM is able bind thrombin and access PC 
bound to EPCR.  This is conclusively demonstrated by both the 4-fold 
increase in APC generation seen on REN-PECAM-EPCR cells, as well as the 
near complete reversal of this effect following EPCR blockade with mAb1560.  
This antibody has been well characterized and is known to inhibit approximately 
70% of protein C binding to mouse EPCR, eliminating to substantial extent, but 
not completely, its ability to accelerate the activation of protein C69. Our results 
were quite consistent with these figures, demonstrating a 75% reduction in 
390 scFv/TM-dependent APC generation following antibody blockade (Figure 
2.5b). 
 The other main finding is the apparent inability of PECAM-bound 390 
scFv/TM to partner with EPCR on MS1 cells.  Two pieces of evidence 
suggest that 390 scFv/TM differs substantially from endogenous TM in terms 
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of its partnering with endogenous co-factors.  First, anti-mTM blocked MS1 
cells treated with a saturating concentration of 390 scFv/TM generate only 
~70% as much APC than unblocked MS1 cells (Figure 2.11).  Since PECAM-
1 is typically expressed at much higher levels per EC than TM (~20 fold 
difference has been reported for HUVECs), this observation indicates a huge 
difference in the amount of APC generated per TM molecule.  Since 390 
scFv/TM and sTM demonstrate similar rates of APC generation in fluid-phase 
assays127, there was no reason to suspect a difference in thrombin binding or 
catalytic efficiency.  Instead, we suspected that our data might be explained 
by a difference in partnering with EPCR.  Indeed, blockade of EPCR using 
mAb1560 had essentially no effect on APC generation by 390 scFv/TM, whereas 
a highly significant 50% reduction was seen on unblocked MS1 cells (Figure 
2.11).  Together, these data strongly suggest that PECAM-anchored 390 
scFv/TM is unable to effectively partner with endogenous EPCR, at least with 
respect to protein C activation. 
 
IV. MATERIALS AND METHODS 
Cell lines and animals 
 MS1 cells were purchased from ATCC (Manassas, VA) and maintained in 
DMEM with 10% FBS and 1X antibiotic-antimycotic (Life technologies, Grand 
Island, NY).  TMpro/pro mice were a generous gift from Dr. Helmut Weiler at the 
Blood Center of Wisconsin. 
 
Antibodies and other reagents 
 Purified anti-PECAM (390) antibody was obtained from BioLegend (San 
Diego, CA).  Anti-mTM polyclonal antibody (AF3894) and anti-EPCR polyclonal 
antibody (AF2749) were purchased from R&D systems (Minneapolis, MN).  Anti-
EPCR blocking antibody, mAb1560, was supplied by the Esmon laboratory.  
Collagenase A and HRP-conjugated Anti-FLAG (M2-HRP) antibody were 
obtained from Sigma Aldrich (St Louis, MO).  PPACK-inactivated thrombin was a 
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generous gift of Sriram Krishnaswamy.  Bovine thrombin was purchased from 
Sigma.  Human protein C zymogen was obtained from Haematologic 
Technologies (Essex Junction, VT). APC substrate S-2366 was purchased from 
Diapharma (West Chester, OH).  Mouse TM-specific siRNA (sc-36687), control 
siRNA (sc-37007), siRNA transfection reagent (sc-29528), and siRNA 
transfection media (sc-36868) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  FITC-conjugated Anti-ICAM-2 antibody, clone 3C4, was from 
Southern Biotech (Birmingham, AL). 
 
Generation of REN-PECAM-EPCR stable cell line 
 A vector containing the entire coding sequence of mouse EPCR and a 
portion of the 5’ and 3’ UTRs (nt 171-1413) was obtained from the Esmon 
laboratory147.  The EPCR cDNA was excised using XbaI and EcoRI and ligated 
into the pcDNA3.1/Zeo(-) vector (Life Technologies, Grand Island, NY).  Since 
REN-PECAM cells already stably express the Geneticin resistance gene, this 
expression vector (which confers resistance to the antibiotic Zeocin) was utilized.  
Cells were transfected with Lipofectamine 2000 and REN-PECAM-EPCR cells 
were selected in media with Geneticin and 250 µg/mL of Zeocin. 
 
Live cell ELISA Assays 
 ELISAs were performed on live cells as previously described142, although 
in the experiments reported here, cell monolayers were incubated with increasing 
concentrations of scFv or scFv/TM fusion protein rather than whole antibodies.  
Since all fusion proteins carry a C-terminal triple FLAG tag, anti-FLAG (M2)-
peroxidase (HRP) conjugate was used as a detection antibody.  In experiments 
involving MS1 endothelial cells, specific binding of 390 scFv/TM was assessed 
by co-incubation with 10-fold excess of parental 390 mAb.  ELISA binding data 
was analyzed and binding parameters (EC50) were determined using PRISM 6.0 
software (GraphPad, San Diego, CA)142. 
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Protein C Activation Assays 
 Generation of APC by scFv/TM fusion was assayed following the 
incubation of confluent REN cell or MS1 monolayers with 390 scFv/TM fusion 
protein.  Cells were washed x 3 with media to remove non-specifically bound 
protein, prior to the addition of 1 nM thrombin and 100 nM protein C.  In all cases, 
protein C activation occurred at 37°C in assay buff er (20 mM Tris, 100 mM NaCl, 
1 mM CaCl2, 0.1% (w/v) bovine serum albumin (BSA), pH 7.5) and the reaction 
was stopped by addition of an excess of hirudin.  In experiments involving MS1 
cells, the monolayer was first treated with 200nM anti-mTM antibody to block 
endogenous TM and then washed x 3 prior to incubation with scFv/TM fusion 
protein.  In experiments involving EPCR blockade, cells were incubated with 
300nM of anti-EPCR antibody (Ab1560) for 15 minutes prior to the addition of 
protein C and thrombin.  This antibody has been well characterized and is known 
to inhibit approximately 70% of protein C binding, eliminating to a substantial 
extent the ability of EPCR to accelerate the activation of protein C by the 
thrombin-TM complex69. 
 
Radioimmunoassays (RIAs) using 125I-labeled Antibodies 
 Anti-EPCR antibody (mAb1560) was directly radioiodinated with [125I]NaI 
(Perkin Elmer, Waltham, MA) and purified using Zeba desalting spin columns 
(ThermoScientific).  Radiolabeling efficiency was > 75% and free iodine was < 
5%, post-purification.  RIAs were performed and binding parameters (Kd, Bmax) 
determined as previously reported142. 
 
siRNA knockdown of mouse TM 
 MS1 cells were transfected with a pool of three mouse TM-specific siRNA 
or control siRNA per manufacturer protocol.  Specific siRNA sequences were not 
made available by the manufacturer.  Cells were plated and allowed to grow until 
they were approximately 75% confluent.  10 pmol of siRNA were mixed with 
transfection reagent and allowed to sit for 30 minutes at room temperature prior 
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to addition to each well of cells.  Cells were exposed for 7 hours, after which they 
were gently washed and incubated with antibiotic-free growth media.  48 hours 
later, cells were lysed for analysis of TM expression by western blot. 
 
shRNA knockdown of mouse TM 
 MS1 cells were transfected with a pool of three mouse TM-specific 
shRNAs using Lipofectamine 2000 (as with siRNA, sequences proprietary to 
manufacturer).  Cells were selected using 4 µg/mL puromycin, a concentration 
found to kill 100% of wild type MS1 cells. 
 
Isolation of TMpro/pro lung endothelial cells 
 Animal studies were carried out in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320 
and 804349) approved by University of Pennsylvania IACUC.  The genotype of 
TMpro/pro mice was verified using genomic DNA obtained from mouse tail tips.  
Lung endothelial cells were isolated as previously described148.  Briefly, neonatal 
pups (7-14 days old) were anaesthetized with ketamine and xylazine and given 
an intramuscular injection of 25 µL of heparin (1000U/mL).  The thoracic cavity 
was entered and 5 mL of ice cold DMEM was injected into the pulmonary 
circulation via the right ventricle.  1 mL of collagenase A (1.0 mg/mL) was 
instilled through the trachea into the lungs, which were then tied off.  The lungs 
were removed and incubated with 5 mL of collagenase A for 30 min at 37°C.  30 
mL of sterile PBS was added and the tube was shaken.  The resulting tissue/cell 
suspension was passed through a 70µm filter, centrifuged, resuspended in 
complete DMEM, and plated onto gelatinized T75 flasks.  The cells were grown 
in M199 medium for 2 days, trypsinized, and subjected to FACS sorting using 
anti-ICAM-2 antibody (clone 3C4).  The sorted cells were pooled, plated at 3x105 
cells/mL in a T25 flask, and split 1:2 at each passage.  
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Data analysis and statistics 
 Results are expressed as mean ± SD unless otherwise noted. Significant 
differences between means were determined using Student’s t-test or one-way 
ANOVA followed by appropriate multiple comparison (Tukey) test.  For 
experiments involving the comparison of multiple dose response curves (e.g. 
APC generation by 390 scFv/TM on REN-PECAM vs. REN-PECAM-EPCR cells), 
two-way ANOVAs were performed.  P<0.05 was considered statistically 
significant.  
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CHAPTER THREE: OPTIMIZATION OF PARTNERING WITH ENDO GENOUS 
EPCR 
 
 
I. INTRODUCTION 
 Having reached the conclusion that 390 scFv/TM anchored to PECAM on 
ECs likely does not partner efficiently with endogenous EPCR, our attention 
turned to potential strategies for enhancing interaction between endothelial 
targeted TM and this key co-factor.  Another cell adhesion molecule, ICAM-1, 
has been shown to localize to apical membrane microdomains on ECs, and to 
cluster in lipid rafts following cytokine stimulation, leukocyte adhesion, and/or 
binding of anti-ICAM-1 antibodies149.  Since EPCR, PAR1, and to some extent, 
TM, are also believed to localize to these membrane microdomains96, we 
hypothesized that anchoring TM to ICAM-1 might allow for enhanced proximity 
and improved partnering with endogenous co-factors and signaling pathways. 
 
II. RESULTS 
 
PECAM-1 vs. ICAM-1 
Relative proximity of PECAM-1 and ICAM-1 to EPCR 
 To assess the relative proximity of EPCR to PECAM-1 and ICAM-1, 
mouse MS1 endothelial cells were stained for each antigen and imaged using a 
fluorescence microscope (Figure 3.1a).  390 mAb, the parental antibody of the 
390 scFv/TM fusion, was used to stain PECAM-1.  YN1/1.7.4 (hereafter referred 
to as YN1) was used to stain ICAM-1.  This mAb has been extensively studied in 
our laboratory and blocks leukocyte LFA-1 interaction150.  In agreement with 
previous reports, most PECAM-1 staining occurred at cell-cell borders136, with 
minimal overlap with EPCR.  In contrast, there was overlap of staining for ICAM-
1 and that for EPCR (Figure 3.1a).  
 
Binding of anti-ICAM and anti-PECAM mAbs to MS1 cells 
 Next, we studied the binding to MS1 cells of 125I-labeled YN1 and 390  
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Figure 3.1. Localization of PECAM-1, ICAM-1, and EP CR on mouse 
endothelial cells 
(a) Immunofluorescence images demonstrate superior co-localization of ICAM-1 
and EPCR, as compared to PECAM-1 and EPCR. (b) Radioimmunoassay data 
using 125I-labeled anti-PECAM (390 mAb) and anti-ICAM (YN1 mAb) to 
determine affinity and number of binding sites per endothelial cell.  
Radioimmunoassays done in quadruplicate (i.e. each point represents four wells 
of cells), data shown are mean ± SD, some error bars too small to be seen. 
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mAbs.  The antibodies had similar subnanomolar affinities (Kd of approx. 0.12 
and 0.22nM, respectively), although PECAM-1 provided ~20-fold more binding 
sites than ICAM-1 (approximately 240,000/cell vs. 12,000/cell, respectively), 
reflecting a substantial difference in the level of cell surface expression of these 
molecules (Figure 3.1b).  Interestingly, according to these data, MS1 have a 
slightly lower number of anti-PECAM binding sites than human umbilical vein 
endothelial cells (HUVECs, ~106 binding sites per cell145), which may reflect 
innate differences between these cell lines.  MS1s are a transformed cell line, 
whereas HUVECs are primary ECs.  Moreover, MS1s are smaller than HUVEC, 
so their number of PECAM copies per cell surface area may be fairly similar. 
 
Construction of an ICAM-targeted scFv/TM Fusion Pro tein 
Cloning of YN1 scFv and fusion to sTM 
 Using a previously reported PCR-based technique, we next cloned an 
anti-ICAM-1 scFv from the YN1 hybridoma151.  Whereas cloning of the VH cDNA 
was straightforward, the typical approach produced only the previously reported 
Y3-Ag 1.2.3 myeloma VL sequence
152 (i.e. the myeloma used to make the YN1 
hybridoma).  As a result, mass spectrometry was used to identify an 8 amino acid 
peptide unique to the ICAM-specific VL, which was then used to produce a full 
length VL cDNA (Figure 3.2).  The VH and VL cDNAs were assembled into a 
complete anti-ICAM-1 YN1 scFv, which was fused to the extracellular domain of 
TM.  The YN1 scFv/TM construct was designed to be identical to 390 scFv/TM, 
with the scFv moiety on the 5’ end (Figure 3.3a).  The purity of YN1 scFv and 
YN1 scFv/TM is shown by gel electrophoresis (Figure 3.3b). 
 
Functional activity of 390 scFv/TM, YN1 scFv/TM, and sTM in solution 
 To ensure that activity of the TM moiety in YN1 scFv/TM was intact, we 
measured APC generation in a fluid-phase assay.  Both YN1 scFv/TM and 390 
scFv/TM fusion proteins were nearly identical to soluble TM in their ability to 
stimulate thrombin-mediated activation of protein C (Figure 3.4). 
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Figure 3.2. Cloning of anti-ICAM V H and V L cDNAs 
(a) A PCR-based approach to cloning of variable heavy and light chain regions 
(VH and VL) utilizes degenerate 5’ primers corresponding to the beginning of the 
1st framework region (FR1) and a 3’ primer corresponding to the start of the 
constant region151. (b) In the case of the YN1 hybridoma, the VH domain was 
readily cloned, but the typical approach amplified only the myeloma-derived VL, 
which is nearly identical to the anti-ICAM VL at the N-terminus of FR1. Mass 
spectrometry was used to identify an 8 amino acid sequence unique to the anti-
ICAM VL. This sequence allowed the majority of the VL to be cloned. A 9 amino 
acid sequence in FR4 was paired with the original 5’ primers to identify the 
residues at the N-terminus of the anti-ICAM VL. 
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Figure 3.3. Design and synthesis of YN1 scFv and sc Fv/TM 
(a) Assembly of VH and VL sequences into scFv and scFv/TM constructs. (b) 
SDS PAGE gel electrophoresis of YN1 scFv, soluble TM, and YN1 scFv/TM 
fusion protein under reducing and non-reducing conditions. 
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Figure 3.4. Fluid-phase APC generation 
Thrombin-dependent activation of protein C was measured in solution and 
compared to soluble TM (sTM). The proteins were mixed with 0.5 nM thrombin 
and a large excess of protein C (1 µM). The reaction was stopped after 15min by 
addition of hirudin. The fusion proteins performed identically to sTM over a range 
of concentrations. 
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Creation of ICAM-1 expressing REN cells 
 As discussed in Chapter 2, the human mesothelioma cell line REN is a 
useful model system, with no expression of mouse PECAM, ICAM, TM, or EPCR 
at baseline (see Figure 2.1).  Although wild type REN cells do express low levels 
of human ICAM-1153, they were found to have no detectable cross-reactivity with 
YN1 mAb by flow cytometry and cell-based ELISA (data not shown).  As a result, 
we created a new stably transfected cell line, REN-mICAM cells, which express 
high levels of mouse ICAM-1. 
 
Binding and functional activity of YN1 scFv/TM on ICAM-expressing REN cells 
 Both YN1 scFv and YN1 scFv/TM demonstrated nanomolar affinity to 
REN-ICAM cells, with no non-specific binding seen on wild type REN cells 
(Figure 3.5a,b).  YN1 scFv/TM demonstrated dose-dependent, thrombin-
mediated activation of protein C on REN-ICAM cells, but not on wild type REN 
cells (Figure 3.6a).  Recombinant sTM showed no activity on either cell type. 
 
EPCR expression potentiates the functional activity of YN1 scFv/TM on REN-
ICAM cells 
 We next assessed the ability of ICAM-anchored YN1 scFv/TM to partner 
with EPCR in the artificial REN cell system.  As had been done for REN-PECAM 
cells, EPCR expression was induced on REN-ICAM cells, producing the stable 
cell line REN-ICAM-EPCR.  As was seen with 390 scFv/TM, EPCR expression 
resulted in ~4-fold enhancement of thrombin-mediated APC generation by YN1 
scFv/TM (Figure 3.6b).  In summary, while bound to their corresponding anchors 
on non-endothelial REN cells, PECAM and ICAM-targeted scFv/TM fusion 
proteins demonstrated roughly equivalent functional activity and similar capacity 
to partner with cellular EPCR, at least with respect to thrombin-dependent APC 
generation. 
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Figure 3.5. Binding of YN1 scFv and scFv/TM to REN- ICAM cells 
Cell based ELISAs show binding of (a) YN1 scFv and  (b) YN1 scFv/TM fusion 
protein to ICAM expressing REN cells.  No significant binding is seen to wild type 
REN cells.  Experiments were done in triplicate (i.e. each point shown represents 
three wells of cells).  Data shown are mean ± SD, although error bars are too 
small to be seen in most cases.  EC50 is shown for each curve. 
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Figure 3.6. APC generation by YN1 scFv/TM on REN-IC AM cells with and 
without EPCR expression 
(a) YN1 scFv/TM activates protein C while bound to ICAM-expressing cells. 
Minimal APC is generated on wild type REN cells, presumably due to lack of 
binding. (b) A ~4-fold increase in APC generation is seen when YN1 scFv/TM is 
anchored to REN-ICAM-EPCR cells, as compared to EPCR-negative 
counterparts.  Differences between groups were highly significant (p < 0.001) at 
all (non-zero) doses of YN1 scFv/TM fusion protein. All experiments were done in 
triplicate (i.e. each point shown represents three wells of cells).  Data shown are 
mean ± SD, although error bars are too small to be seen in some cases. 
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Studies on Mouse Endothelial Cells 
Binding of YN1 scFv/TM to quiescent and TNF-stimulated endothelial cells 
 The binding of YN1 scFv/TM was tested on MS1 cells.  Unlike most 
endothelial cells (e.g., HUVEC), quiescent MS1 cells express significant levels of 
ICAM-1, although they demonstrate a similar ~1.5-fold increase in response to 
TNF or other cytokine stimulation.  YN1 scFv/TM demonstrated ICAM-specific 
binding to MS1 cells, as evidenced by near complete inhibition of binding by a 
10-fold excess of parental antibody (Figure 3.7).  Likewise, stimulation of the 
cells with mouse TNF demonstrated a small but significant increase in fusion 
protein binding.  Calculated affinity constants were similar to those seen in REN-
ICAM cell experiments. 
 
Functional activity of EC-bound 390 scFv/TM and lack of EPCR partnering 
 We employed anti-mTM antibody blockade (described in Chapter 2) to 
assess protein C activation by YN1 scFv/TM anchored to MS1 cells.  APC 
generation was compared to unblocked MS1 cells and antibody blocked MS1 
cells treated with 40nM 390 scFv/TM.  As with 390 scFv/TM, a high concentration 
of YN1 scFv/TM was used (40nM), in order to saturate available binding sites.  
The maximum numbers of PECAM- and ICAM-binding sites were known from 
our radioimmunoassays (Figure 3.1b).  Despite a 20-fold difference in binding 
sites, only a ~1.5 fold difference was seen in the level of APC generation (Figure 
3.8a).  We assessed the role of EPCR using the mAb1560 blocking antibody and 
found that YN1 scFv/TM-treated MS1 cells showed a 50% reduction in protein C 
activation, similar to unblocked MS1s and in contrast to 390 scFv/TM-treated 
cells (Figure 3.8a). 
 In order to directly compare the activity of EC-bound YN1 scFv/TM and 
390 scFv/TM, APC generation was normalized to the number of binding sites per 
cell.  This analysis revealed that YN1 scFv/TM has ~15-fold greater functional 
activity then 390 scFv/TM, while anchored to MS1 cells (Figure 3.8b). 
 
 
 53 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Binding of YN1 scFv/TM to quiescent and  activated MS1 cells 
Specificity is demonstrated by inhibition of binding by 10-fold excess of parental 
390 mAb. All experiments were done in triplicate (i.e. each point shown 
represents three wells of cells).  Data shown are mean ± SD, although error bars 
are too small to be seen in some cases. 
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Figure 3.8. APC generation by PECAM- vs. ICAM-ancho red scFv/TM on 
antibody blocked MS1 cells 
(a) Despite a 20-fold difference in the number of PECAM vs. ICAM binding sites, 
antibody-blocked MS1 cells treated with 390 scFv/TM generate only ~1.5-fold 
more APC than those treated with YN1 scFv/TM.  Moreover, APC generation by 
YN1 scFv/TM, but not 390 scFv/TM, is affected by blockade of EPCR (p < 
0.001).  The 50% reduction is similar to what is seen with unblocked MS1 cells 
(reflecting the activity of endogenous TM). (b) Normalization of APC generation 
to number of binding sites shows that functional activity of YN1 scFv/TM is ~15-
fold greater than 390 scFv/TM (p << 0.001).  Experiments done in triplicate.  Data 
shown are mean ± SD. 
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Figure 3.9. YN1 scFv/TM reduces MIP-2 in a mouse mo del of lung injury 
(a) Timeline of intratracheal LPS lung injury model.  In experiments assessing 
endothelial barrier dysfunction, a tracer amount of 125I-labeled albumin was 
injected 5 minutes prior to LPS administration. (b) Concentration of the critical 
neutrophil chemokine, MIP-2, in bronchoalveolar lavage (BAL) fluid.  Data shown 
are mean ± SD, with number of animals as shown. 
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Figure 3.10. YN1 scFv/TM reduces inflammatory marke r expression and 
endothelial barrier dysfunction in mouse lung injur y model 
(a) mRNA transcript levels of pro-inflammatory cell adhesion molecules, VCAM-1 
and E-selectin, in lung homogenate. (b) Endothelial barrier dysfunction, as 
measured by leakage of 125I-labeled albumin from blood into lung interstitium 
and/or alveolar space.  All data shown are mean ± SD, with number of animals 
as shown.  
 
 57 
In vivo Experiments 
Endothelial protective effects of YN1 scFv/TM and 390 scFv/TM in a mouse 
model of acute lung injury 
 Anti-inflammatory effects of YN1 scFv/TM and 390 scFv/TM were then 
compared in a model of lung inflammation, in which mice receive an intratracheal  
(IT) injection of endotoxin154.  The fusion proteins, or PBS vehicle, were injected 
intravenously 30 minutes prior to LPS challenge (Figure 3.9a).  Relevant indices 
of lung inflammation and injury were measured, including the level of MIP-2 in 
bronchoalveolar lavage fluid (Figure 3.9b), expression of cell adhesion molecules 
VCAM-1 and E-selectin in lung tissue homogenate (Figure 3.10a), and 
extravascular leakage of radiolabeled albumin injected intravenously and 
detected in the lungs (Figure 3.10b).  While both YN1 scFv/TM and 390 scFv/TM 
showed evidence of protection, the ICAM-targeted fusion protein was more 
effective in all cases. 
 
III. CONCLUSIONS 
 The data presented in this chapter support the notion that the ability of 
endothelial targeted scFv/TM fusion proteins to interact with endogenous 
EPCR depends on which surface determinant is targeted, and that this 
variable may have significant therapeutic implications, with YN1 scFv/TM 
fusion demonstrating more potent protective effects in vivo.  Our data, along 
with prior reports regarding the distribution of ICAM and PECAM on the 
endothelial membrane136,137,149, suggest that the proximity of the TM fusion to 
EPCR may be the critical factor.  Figure 3.11 shows a simplified model of an 
endothelial cell with the TM fusion proteins bound to their target ligands.  The 
figure accurately depicts the fusion proteins binding the domains of PECAM-1 
and ICAM-1 which lie furthest from the plasma membrane, consistent with the 
location of their target epitopes142,150.  The schematic highlights the proposed 
difference in proximity to the EPCR/Protein C complex, which may account for 
our experimental observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Schematic representation of TM fusion proteins anch ored to 
The proximity of ICAM
account for its enhanced activity 
 
58 
 
the endothelial plasmalemma 
-targeted scFv/TM to endogenous EPCR/Protein C may 
in vitro and in vivo
 
 
. 
 
 59 
 It is worth noting that these results align with the general notion that 
anchoring agents to distinct determinants on the same target cell may produce 
distinct outcomes, due to the differing functions, location, surface density, and  
trafficking of these surface molecules. For example, our laboratory previously 
reported that binding of the H2O2-producing enzyme, glucose oxidase (GOX), to 
endothelial cells induced varying degrees of vascular damage, depending on 
whether PECAM or TM was chosen as the surface target155.  The variation in 
outcome in those experiments was attributed to the substantially different 
function of these two surface molecules and the consequences of their blockade 
by GOX conjugates.  In contrast, it is difficult to attribute the current results to any 
functional difference between ICAM and PECAM, two closely related proteins 
which both support leukocyte adhesion, pro-inflammatory signaling, and uptake 
of antibody conjugates via a similar endocytic mechanism156,157.  For this reason, 
we believe that the most logical explanation for our current experimental results 
is the distinct localization of ICAM and PECAM on the endothelial membrane and 
their differing capacity to allow interaction of anchored scFv/TM with EPCR. 
 In summary, our first approach for enhancing partnering of endothelial-
targeted TM and EPCR involved the rational selection of an endothelial 
determinant, ICAM-1, based on knowledge of its membrane distribution.  We 
constructed and synthesized a recombinant ICAM-targeted scFv/TM fusion 
protein.  In comparing its function to that of PECAM-targeted scFv/TM, we found 
evidence of superior functional activity on ECs, partnering with endogenous 
EPCR, and enhanced protective effects in a mouse model of lung injury.  
Together, these results suggest that delivery of recombinant TM to the 
endothelial membrane in a way that mimics its natural distribution and optimizes 
interaction with endogenous co-factors is more effective.  These findings 
underscore the complexity of targeting biotherapeutics to the plasmalemma, and 
suggest that precision on a nanometer scale is necessary for optimal 
biotherapeutic effect. 
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IV. MATERIALS AND METHODS 
Cell lines 
 YN1 hybridoma and MS1 cells were purchased from ATCC (Manassas, 
VA).  YN1 cells were cultured in RPMI 1640 supplemented with 10% (v/v) fetal 
bovine serum (FBS).  MS1 cells were maintained in DMEM with 10% FBS and 
1X antibiotic-antimycotic (Life technologies, Grand Island, NY). 
 
Antibodies and other reagents 
 Purified anti-PECAM (390) and anti-ICAM (YN1) antibodies were obtained 
from BioLegend (San Diego, CA).  Anti-TM polyclonal antibody (AF3894) and 
anti-EPCR polyclonal antibody (AF2749) were purchased from R&D systems 
(Minneapolis, MN).  Anti-EPCR blocking antibody, mAb1560, was supplied by the 
Esmon laboratory.  HRP-conjugated Anti-FLAG (M2-HRP) antibody was obtained 
from Sigma Aldrich (St Louis, MO).  Alexa Fluor-labeled secondary antibodies 
were purchased from Life Technologies (Grand Island, NY). Bovine thrombin, 
LPS (serotype B4), and mouse TNF were purchased from Sigma.  Human 
protein C zymogen was obtained from Haematologic Technologies (Essex 
Junction, VT). APC substrate S-2366 was purchased from Diapharma (West 
Chester, OH). 
 
Endothelial cell immunofluorescence staining 
 MS1 cell monolayers were grown in 8 well µ-slides (Ibidi, Verona, WI) and 
fixed for 20 minutes at room temperature (RT) with Histochoice (Amresco, Solon, 
OH).  In some cases, cells were treated with 10 ng/mL mouse TNF for 8 hours 
prior to fixation.  After three washes, cells were blocked with 3% (w/v) BSA in 
HBSS for 1 hour at RT.  Cells were stained with either anti-PECAM (390, 15 
µg/mL) or anti-ICAM (YN1, 1 µg/mL) mAbs, in addition to polyclonal goat anti-
mouse EPCR (0.5 µg/mL) for 2 hours at RT.  Cells were washed three times with 
0.1% Tween in HBSS and then stained with Alexa Fluor 594 anti-rat (1:200) and 
Alexa Fluor 488 anti-goat (1:1000).  After 1 hour incubation, cells were washed 
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four times with 0.1% Tween in HBSS and once in PBS.  ProLong Gold Antifade 
reagent with DAPI (Life technologies, Grand Island, NY), and a coverslip was 
applied and cells were allowed to dry overnight prior to immunofluorescence 
imaging. 
  
Cloning of anti-ICAM VL and VH cDNAs 
 Total cellular RNA was isolated from YN1 hybridoma cells using the 
RNeasy kit (Qiagen, Valencia, CA).  Combined reverse transcription and PCR 
was performed using SuperScript One Step RT-PCR kit (Life Technologies, 
Grand Island, NY) and previously reported FR1 region primers151.  Mass 
spectrometry to identify an 8-aa sequence unique to the ICAM-specific VL was 
done by the Core Facility at the University of Pennsylvania using purified YN1 
antibody that had been run on a denaturing SDS PAGE gel and excised.  
Degenerate PCR primers were synthesized based on this sequence and used to 
produce a full length VL distinct from the known Y3-Ag 1.2.3 myeloma VL 
sequence152. 
 
Assembly and expression of anti-ICAM scFv and anti-ICAM scFv/TM constructs 
 Completed anti-ICAM VL and VH cDNAs were assembled into constructs 
encoding anti-ICAM scFv and the anti-ICAM scFv/TM fusion protein.  In each 
case, VH and VL sequences were separated by a (GGGGS)3 linker, and a triple 
FLAG tag was appended to the 3’ end (C terminus) for purposes of purification 
and detection.  The YN1 scFv moiety was separated from the extracellular 
domain of TM (amino acids Leu17-Ser517) by an (SSSSG)2AAA linker.  Both 
proteins were expressed in S2 cells and purified using a C-terminal triple FLAG 
tag.  Purity was assessed using SDS-PAGE. 
 
Generation of REN-derived Stable Cell Lines 
 REN-mICAM cells. A full-length cDNA for mouse ICAM-1 was purchased 
from Thermo Scientific (Rockford, IL).  The clone was sequenced and found to 
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contain the entire coding sequence of mouse ICAM-1 and a portion of the 5' and 
3' UTRs (nt 46-2440) between EcoRI and XbaI restriction enzyme sites.  The 
clone was excised and ligated into the pcDNA3 mammalian expression vector, 
and transfected into REN cells using Lipofectamine 2000 (Life Technologies, 
Grand Island, NY).  Stably expressing cells were selected in media containing 
200 µg/mL of Geneticin (Life Technologies, Grand Island, NY). 
  
 REN-mICAM-mEPCR cells.  A vector containing the entire coding 
sequence of mouse EPCR and a portion of the 5’ and 3’ UTRs (nt 171-1413) was 
obtained from the Esmon laboratory147.  The EPCR cDNA was excised using 
XbaI and EcoRI and ligated into the pcDNA3.1/Zeo(-) vector (Life Technologies, 
Grand Island, NY).  Since REN-ICAM cells already stably express the Geneticin 
resistance gene, this expression vector (which confers resistance to the antibiotic 
Zeocin) was utilized.  Cells were transfected with Lipofectamine 2000 and REN-
ICAM-EPCR cells were selected in media with Geneticin and 250 µg/mL of 
Zeocin. 
 
Live Cell ELISA Assays 
 Enzyme-linked Immunosorbent Assays (ELISAs) were performed on live 
cells as described in Chapter 2. ELISA binding data was analyzed and binding 
parameters (EC50) were determined using PRISM 6.0 software (GraphPad, San 
Diego, CA)142. 
 
RIAs using 125I-labeled antibodies 
 390 and YN1 mAbs were directly radioiodinated with [125I]NaI (Perkin 
Elmer, Waltham, MA) and purified using Zeba desalting spin columns 
(ThermoScientific).  In all cases, radiolabeling efficiency was > 75% and free 
iodine was < 5%, post-purification.  RIAs were performed and binding parameters 
(Kd, Bmax) determined as previously reported
142. 
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Protein C activation assays 
 Generation of APC by cell-bound scFv/TM fusion was assayed as 
described in Chapter 2.  For fluid-phase APC generation experiments, sTM, 390 
scFv/TM, and YN1 scFv/TM were each mixed with 0.5nM thrombin and 1 µM 
protein C in a micro-Eppendorf tube.  In all cases, protein C activation occurred 
at 37°C in assay buffer (20 mM Tris, 100 mM NaCl, 1  mM CaCl2, 0.1% (w/v) 
BSA, pH 7.5) and the reaction was stopped by addition of an excess of hirudin.  
As described in Chapter 2, MS1 cell monolayers were first treated with anti-TM 
antibody to block endogenous TM and then washed x 3 prior to incubation with 
scFv/TM fusion protein.  The amount of APC generated by cell-bound fusions in 
these experiments was normalized to the number of binding sites per cell, as 
determined in MS1 RIAs (approximately 240,000/cell for PECAM-1 and 
12,000/cell for ICAM-1).  Antibody blockade of EPCR was performed as 
described in Chapter 2, using 300nM of anti-EPCR antibody (Ab1560) for 15 
minutes prior to the addition of protein C and thrombin. 
 
IT LPS model 
 Animal studies were carried out in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320 
and 804349) approved by University of Pennsylvania IACUC.  C57BL/6 male 
mice weighing 20-30 gm were anaesthetized and placed in a supine position.  
Acute lung injury was induced via IT injection of 2 mg/kg of endotoxin in a volume 
of 100 µL of PBS.  Endotoxin injection was followed immediately by injection of 
150 µL of air, to ensure even distribution of LPS throughout all distal airspaces. 
In relevant experiments, anti-PECAM scFv/TM, anti-ICAM scFv/TM, or PBS 
vehicle and 125I-labeled albumin were injected intravenously prior to LPS 
administration as shown.  6 hours after induction of lung injury, blood was 
withdrawn from the inferior vena cava and animals were euthanized. 
 In experiments involving tracing of 125I-labeled albumin, a catheter was 
placed in the pulmonary artery and the pulmonary circulation was gently flushed 
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with PBS prior to the harvesting of organs.  The amount of radioactivity in the 
blood and lungs was measured using a Wizard2 2470 gamma counter 
(PerkinElmer, Waltham, MA).  The localization ratio of 125I-albumin (calculated as 
(% injected dose present in lung/g of lung tissue)/blood level) was used as a 
surrogate for pulmonary edema. 
 In other experiments, bronchoalveolar lavage was performed via a 19-
gauge stainless steel catheter (Harvard Apparatus, Holliston, MA) placed in the 
trachea and secured via a 5-0 silk suture.  Each animal was lavaged twice with 
0.8 mL of ice-cold PBS.  The lavages were pooled and MIP-2 was quantified 
using a Quantikine ELISA kit (R&D systems, Minneapolis, MN).  For 
quantification of VCAM-1 and E-selectin mRNA, lungs were homogenized with 
steel beads (Sigma) and a Tissue Lyser II (Qiagen).  Total RNA was isolated with 
RNeasy kit and cDNA was synthesized using the Transcriptor 1st Strand cDNA 
Synthesis Kit (Roche Applied Science, Indianapolis, IN).  qPCR was performed 
using the FastStart DNA MasterPLUS kit (SYBR green) and a Lightcycler 1.5 
carousel-based system (Roche Applied Science).  Validated Quantitect primers 
for mouse VCAM-1, E-selectin, and actin (housekeeping control) were utilized 
(Qiagen, Valencia, CA). 
 
Data analysis and statistics 
 Results are expressed as mean ± SD unless otherwise noted. Significant 
differences between means were determined using Student’s t-test or one-way 
ANOVA followed by appropriate multiple comparison (Tukey) test.  For 
experiments involving the comparison of multiple dose response curves (e.g. 
APC generation by YN1 scFv/TM on REN-ICAM vs. REN-ICAM-EPCR cells), 
two-way ANOVAs were performed.  P<0.05 was considered statistically 
significant. 
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CHAPTER FOUR: DUAL TARGETING OF TM AND EPCR FUSION PROTEINS 
TO THE ENDOTHELIUM 
 
 
I. INTRODUCTION 
 Although anchoring TM to ICAM-1 appears to improve partnering with 
endogenous EPCR, PECAM-1 has desirable features from the standpoint of 
vascular immunotargeting48.  Its constitutive, stable, and high level of expression 
throughout the vasculature makes it the preferred choice for targeting of 
prophylactic agents, e.g., prior to a predictable vascular insult like 
cardiopulmonary bypass or organ transplantation.  Likewise, PECAM-1 differs 
from other pan-endothelial determinants (e.g., angiotensin converting enzyme, or 
ACE), in that it is relatively poorly internalized by ECs, allowing for surface 
targeting of TM fusion proteins.  Finally, anchoring of scFv/TM to PECAM-1 is 
unlikely to be deleterious, and if anything, would be expected to have an anti-
inflammatory effect due to inhibition of transendothelial leukocyte migration158,159. 
 As a result, we wanted to explore the possibility of utilizing PECAM-1 as a 
surface determinant for dual targeting of recombinant scFv/TM and scFv/EPCR.  
By anchoring both proteins to PECAM-1, we hypothesized that we would achieve 
sufficient proximity to allow enzymatic partnering.  Another reason for choosing 
PECAM-1 as the surface determinant was our discovery of the “collaborative 
enhancement” phenomenon, in which paired antibodies to adjacent, distinct 
epitopes on PECAM-1 increase each other’s binding to the endothelium in vitro 
and in vivo142.  Based on this mechanism, we hypothesized that scFv/TM and 
scFv/EPCR fusion proteins directed to paired PECAM-1 epitopes would enhance 
– rather than competitively inhibit – each other’s binding.  Altogether, dual 
targeting of these therapeutic fusion proteins would have the capacity to 
accelerate protein C activation via two distinct mechanisms: 1. collaborative 
enhancement of binding and 2. enzymatic partnering of the TM and EPCR 
moieties. 
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II. RESULTS 
 
Construction of a PECAM-targeted scFv/EPCR Fusion P rotein 
Cloning of Mec13 scFv and fusion to mouse EPCR 
 Previous studies in our laboratory demonstrated that mAbs 390 and 
Mec13.3 (hereafter referred to as Mec13), which bind to distinct, but adjacent, 
epitopes located in the extracellular Ig-domain 2 of mouse PECAM-1160, enhance 
each others binding (Figure 4.1a).  This phenomenon of “collaborative 
enhancement” exists in both transfected (i.e. REN-PECAM) cells and mouse 
endothelial cells (Figure 4.1b) and also contributes to enhanced endothelial 
binding of antibodies in vivo (Figure 4.1c)142. 
 To take advantage of collaborative enhancement with 390 scFv/TM, we 
wanted to design the scFv/EPCR fusion protein using an antibody fragment 
derived from the Mec13 hybridoma.  As in the cloning of the YN1 scFv described 
in Chapter 3, the Mec13 VH cDNA was easily identified using degenerate 
framework region 1 (FR1) primers.  Once again, however, this approach 
produced only a non-functional, myeloma-derived VL cDNA, with an in frame stop 
codon in the FR1 region (Figure 4.2a).  As a result, the Mec13 light chain was 
sequenced using the N-terminal Edman technique.  The first 7 amino acids of the 
FR1 region were identified and used to clone of a full length VL cDNA (Figure 
4.2a).  The VH and VL cDNAs were assembled into a complete anti-PECAM-1 
Mec13 scFv, which was fused to the extracellular domain of EPCR.  The scFv 
moiety was positioned on the 3’ end, to keep the protein C binding site of EPCR 
(located on the N-terminal end) freely accessible (Figure 4.2b).  Recombinant 
soluble mouse EPCR (sEPCR) was synthesized as well.  The purity of each 
protein is shown by gel electrophoresis (Figure 4.2c). 
 
Binding of Mec13 scFv/EPCR to REN-PECAM cells and immobilized Protein C 
 Both Mec13 scFv and the Mec13 scFv/EPCR bound to REN-PECAM-  
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Figure 4.1. Collaborative enhancement of mAb bindin g to PECAM-1 
(a) Amino acid location of epitopes for mAbs 390 and MEC13 on Ig-domain 2 
(IgD2) of mouse PECAM-1 (b) Collaborative binding studies of mAbs 390 and 
MEC13 on REN-PECAM cells.  Whereas unlabeled self-paired mAb 390 and 
mAb MEC13 competitively inhibit binding of [125I]-mAb390 and [125I]-mAb MEC13 
to REN-PECAM cells, mAb pairs [125I]-mAb 390/MEC13.3 and [125I]-mAb 
MEC13.3/390 enhance binding by 1.5 fold and 2.7 fold, respectively. (c) In vivo 
endothelial targeting of [125I]-mAb to PECAM-1 is enhanced by paired anti-
PECAM-1 mAb.  Lung:blood ratio for [125I]-mAb 390/mAb MEC13 and [125I]-mAb 
MEC13.3/mAb 390 pairs increases 3.4 fold.  The dotted red line is the lung:blood 
ratio of [125I]-IgG at 30 minutes.  Data is reported as the standard error of the 
mean of n = 4–5 animals (***, P = 0.001).  (All data reproduced from Chacko A-M 
et al. PLoS One 2012, reference 142) 
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Figure 4.2. Cloning, assembly, and purification of Mec13 scFv, sEPCR, 
and Mec13 scFv/EPCR fusion protein 
(a) The Mec13 VL  and the myeloma-derived VL are nearly identical at the N-
terminus of FR1 region.  N-terminal (Edman) sequencing was used to identify a 
one amino acid difference (Gln vs. Val), which ultimately enabled amplification of 
a full length Mec VL cDNA. (b) Assembly of VH and VL sequences into Mec13 
scFv and Mec13 scFv/EPCR constructs.  An sEPCR construct was also made  
(c) Purity of recombinant proteins as shown by SDS PAGE. 
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Figure 4.3. Function of scFv and EPCR moieties of M ec13 scFv/EPCR 
fusion protein 
(a) Cell based ELISAs show that binding of Mec13 scFv/EPCR fusion protein to 
PECAM expressing REN cells is similar to that of Mec13 scFv.  No significant 
binding is seen to wild type REN cells.  (b) Mec13 scFv/EPCR fusion protein 
binds immobilized protein C in nearly identical manner as sEPCR.  Empty 
triangles () indicate non-specific binding of Mec13 scFv/EPCR to BSA-coated 
wells.  All experiments were done in triplicate (each point shown represents three 
wells), with SD shown.  
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cells, but not wild type REN cells (Figure 4.3a).  Having confirmed the function of 
the scFv moiety, the function of the EPCR moiety was tested by comparing the 
binding of Mec13 scFv/EPCR and sEPCR to immobilized protein C.  Both 
proteins showed equal binding, with no non-specific binding to albumin-coated 
wells (Figure 4.3b). 
 
Functional Activity of Mec13 scFv/EPCR 
Creation of TM expressing REN wt and REN-PECAM cells 
 To assess the ability of Mec13 scFv/EPCR to augment protein C 
activation by TM/thrombin complex on the cell surface, we generated a series of 
transfected REN cells stably expressing mouse TM and/or PECAM-1 on their 
surface.  Thrombin-dependent protein C activation was measured on REN-
PECAM-TM cells, which stably express both mouse PECAM-1 and TM (Figure 
4.4a), and compared to APC generation on REN-TM and REN-PECAM cells.  As 
expected, REN-TM and REN-PECAM-TM cells, but not TM-lacking cells (REN 
and REN-PECAM) exerted thrombin dependent activation of protein C (Figure 
4.4b). 
 
Mec13 scFv/EPCR enhances APC generation on REN-PECAM-TM cells 
 Mec13 scFv/EPCR stimulated thrombin-dependent production of APC by 
REN-PECAM-TM, but not REN-TM cells (Figure 4.4c).  This indicates that the 
EPCR fusion protein is able to partner with TM in the cell membrane while bound 
to PECAM.  No such effect was seen with Mec13 scFv or sEPCR (Figure 4.4d), 
confirming the need for both functional moieties in the fusion protein to bind to 
target cells and partner with TM in the plasma membrane.   
 
Dual Targeting of Mec13 scFv/EPCR and 390 scFv/TM t o REN Cells 
Mec13 scFv/EPCR and 390 scFv/TM demonstrate collaborative enhancement 
 Collaborative enhancement of binding was originally described with paired  
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Figure 4.4. Functional activity of Mec13 scFv/EPCR fusion protein 
(a) Western blotting confirms expression of mouse TM on REN-PECAM-TM and 
REN-TM cells. (b) APC generation assay on REN-PECAM-TM and REN-TM 
cells confirms surface localization and functional activity of expressed TM. (c) 
Mec13/EPCR enhances protein C activation by surface expressed TM on REN-
PECAM-TM cells.  No effect is seen on REN-TM cells, to which the fusion does 
not bind.  (d) Mec13 scFv and sEPCR (each 150 nM) have no effect on APC 
generation on REN-PECAM-TM cells. 
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antibodies to PECAM-1 (Figure 4.1).  We were interested to determine if TM and 
EPCR fusion proteins directed to the same paired epitopes would demonstrate 
the same phenomenon.  Indeed, both Mec13 scFv and Mec13 scFv/EPCR 
increased the binding of 390 scFv/TM to REN-PECAM cells (Figure 4.5a).  
Likewise, 390 scFv and 390 scFv/TM increased the binding of Mec13 
scFv/EPCR to these cells (Figure 4.5b).  
 
Mec13 scFv/EPCR enhances protein C activation by 390 scFv/TM on REN-
PECAM cells 
 We next studied the activation of protein C on REN-PECAM cells following 
dual targeting of scFv/TM and scFv/EPCR fusion proteins.  Mec13 scFv/EPCR 
demonstrated a dose-dependent enhancement of thrombin-dependent APC 
generation in cells also treated with 390 scFv/TM, with nearly ~5-fold increase 
seen at the highest dose (Figure 4.6a). 
 In theory, both enhanced binding and functional partnering between the 
TM and EPCR moieties may contribute to the 5-fold increase observed.  We 
conducted several experiments to determine the relative contribution of each 
effect.  First, Mec13 scFv (lacking the EPCR moiety) was used to estimate the 
“binding effect” and provided ~2-fold stimulation of APC production by 390 
scFv/TM (Figure 4.6b).  Conversely, we estimated the contribution of enzymatic 
partnering (the “EPCR effect”) by using mAb1560 to block the interaction of 
EPCR and murine protein C.  In REN-PECAM cells treated with Mec13 
scFv/EPCR and 390 scFv/TM, blockade of EPCR reduced APC generation by 
~2-fold to almost exactly the level seen in cells co-treated with TM fusion protein 
and Mec13 scFv (Figure 4.6b).  Taken together, these data reveal two distinct 
mechanisms, which make roughly equivalent contributions to the net effect of 
Mec13 scFv/EPCR on the generation of APC by 390 scFv/TM. 
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Figure 4.5. Mec13 scFv/EPCR and 390 scFv/TM fusion proteins 
demonstrate collaborative enhancement of binding 
(a) In agreement with experiments done using intact antibodies, Mec13 scFv and 
Mec13 scFv/EPCR enhance the binding of 390 scFv/TM and (b) 390 scFv/TM 
enhances the binding of Mec13 scFv/EPCR to REN-PECAM cells.  Experiments 
were done in triplicate (each point shown represents three wells), with SD shown. 
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Figure 4.6. Mec13 scFv/EPCR enhances APC generation  by 390 scFv/TM 
via two distinct mechanisms 
(a) Co-treatment of REN-PECAM cells with Mec13 scFv/EPCR produces a dose 
dependent increase in APC generation by surface bound 390 scFv/TM.  (b) 
Additional experiments suggest that two distinct effects contribute to the action of 
Mec13 scFv/EPCR fusion protein: 1. an increase in 390 scFv/TM binding and 2. 
partnering of cell bound TM and EPCR.  The binding effect, demonstrated by co-
treatment of cells with 390 scFv/TM and Mec13 scFv (150 nM), is significant (p = 
0.004).  Likewise, co-treatment with 390 scFv/TM and Mec13 scFv/EPCR results 
in significantly greater APC generation (p < 0.001 compared to all other groups) 
and is demonstrated to be EPCR-dependent via the use of an anti-EPCR 
monoclonal antibody.  All experiments were done in triplicate.  Data shown are 
mean ± SD. 
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Dual Targeting on Mouse Endothelial Cells 
Mec13 scFv/EPCR enhances protein C activation by 390 scFv/TM on MS1 cells 
 Using the anti-mTM antibody blockade technique described in Chapter 2, 
we measured protein C activation by 390 scFv/TM anchored to MS1 cells, with  
and without addition of Mec13 scFv/EPCR.  Similar to what had been seen on 
REN-PECAM cells, Mec13 scFv/EPCR increased protein C activation by 390 
scFv/TM.  Likewise, use of Mec13 scFv and EPCR blocking mAb revealed a 
similar contribution of two distinct mechanisms by which the EPCR fusion protein 
exerts its effect: collaborative enhancement of binding and enzymatic partnering 
(Figure 4.7). 
 
Construction and characterization of YN1 scFv/EPCR 
 We next sought to determine if anchoring TM and EPCR to different 
surface molecules would achieve effects similar to what was seen with Mec13 
scFv/EPCR and 390 scFv/TM.  To test this, we designed and synthesized an 
anti-ICAM YN1 scFv/EPCR fusion protein (Figure 4.8a).  We confirmed its 
binding to ICAM-expressing cells and its effect on APC generation by TM in a 
series of experiments similar to those described above.  In this case we utilized 
REN-ICAM-TM cells, instead of REN-PECAM-TM cells (Figure 4.8b).  Anti-ICAM 
scFv/EPCR bound REN-ICAM-TM cells, but not REN-TM cells (Figure 4.8c), and 
enhanced protein C activation by membrane TM (Figure 4.8d).  Therefore, anti-
ICAM scFv/EPCR displayed binding and functional activity, including TM 
partnering, similar to Mec13 scFv/EPCR. 
 
YN1 scFv/EPCR does not enhance protein C activation by 390 scFv/TM 
 We utilized YN1 scFv/EPCR and 390 scFv/TM fusion proteins to test 
anchoring TM and EPCR to different surface molecules.  In contrast to Mec13 
scFv/EPCR, no enhancement of protein C activation was seen with YN1 
scFv/EPCR fusion protein, nor was there any effect of the EPCR blockade  
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Figure 4.7. Mec13 scFv/EPCR enhances APC generation  by 390 scFv/TM 
on antibody blocked MS1 cells 
(a) APC generation by 390 scFv/TM was assayed on anti-mTM blocked MS1 
cells.  The residual activity of endogenous TM is indicated by the dotted line.  
Mec13 scFv/EPCR (100 nM) enhances APC generation by cell bound 390 
scFv/TM.  As seen in REN-PECAM cell experiments, two independent 
mechanisms can be discerned: a binding effect (p < 0.001 compared to 390 
scFv/TM alone) and an EPCR-dependent effect (p < 0.001 compared to all other 
groups).  Of note, EPCR blockade slightly reduces the residual activity of 
endogenous TM, as indicated by the lower dotted line.  Experiments were done 
in triplicate.  Data shown are mean ± SD. 
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Figure 4.8. Construction and characterization of YN 1 scFv/EPCR 
(a) Molecular design of YN1 scFv/EPCR  (b) Western blot of REN-ICAM-TM cells 
demonstrates expression of mouse ICAM-1 and TM. (c) Cell-based ELISA 
confirms binding of anti-ICAM/TM to REN-ICAM-TM but not REN-TM cells. (d) 
YN1 scFv/EPCR enhances activation of protein C by surface expressed TM 
when bound to REN-ICAM-TM cells.  ELISA and APC generation experiments 
done in triplicate, data shown are mean ± SD. 
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Figure 4.9. YN1 scFv/EPCR does not enhance protein C activation by 390 
scFv/TM on MS1 cells 
Anchoring TM and EPCR to different endothelial surface determinants on MS1 
cells (PECAM-1 and ICAM-1, respectively), does not enhance APC generation (p 
= 0.75).  Antibody blockade of EPCR has no effect, other than a small reduction 
in the residual activity of endogenous TM. Experiments were done in triplicate; 
data shown are mean ± SD. 
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Figure 4.10. Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM reduces 
pulmonary edema in a mouse model of lung injury 
(a) Timeline of intratracheal LPS lung injury model.  (b) Pulmonary edema, as 
determined by leakage of 125I-labeled albumin from the blood into lung 
interstitium and/or alveolar space, is reduced by pre-treatment with 390 scFv/TM.  
Co-administration of Mec13 scFv/EPCR, but not anti-ICAM scFv/EPCR, 
significantly enhances protection.  Pre-treatment with Mec13 scFv/EPCR alone 
and co-administration of Mec13 and 390 scFvs have no effect. Data shown are 
mean ± SD, with n=4-5 mice in each group.  Dotted line indicates level of albumin 
leakage seen in control animals that did not receive LPS. 
  
 
 80 
antibody (Figure 4.9). 
 
In vivo Experiments 
Dual targeting of fusion proteins in a mouse model of acute lung injury 
 Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM was then tested in 
a mouse model of lung inflammation/injury and compared to treatment with the 
TM fusion protein alone.  Pulmonary edema induced by LPS endotoxin challenge 
was measured by uptake of IV injected 125I-labeled albumin. Fusion proteins, or 
PBS vehicle, were injected IV 30 minutes prior to LPS challenge (Figure 4.10a). 
Dual targeting of Mec13 scFv/EPCR and 390 scFv/TM maximally effectively 
reduced pulmonary edema, with a significant improvement compared to 
treatment with the TM fusion protein alone.  Administration of Mec13 scFv/EPCR 
alone had no effect, nor did sequential injection of Mec13 and 390 scFvs.  The 
latter was done as a control to ensure that the effects on barrier function were not 
simply the result of the two antibody fragments binding to PECAM-1.  Finally, co-
treatment with 390 scFv/TM and YN1 scFv/EPCR resulted in no additional 
protection, consistent with our observations on MS1 cells (Figure 4.10b). 
 
III. CONCLUSIONS 
 This chapter describes an alternate strategy for replicating the enzymatic 
partnering seen with endogenous TM and EPCR, namely dual targeting of both 
recombinant molecules to the same endothelial surface determinant. As 
hypothesized, our in vitro experiments indicate two distinct mechanisms by which 
the Mec13 scFv/EPCR enhances the activity of 390 scFv/TM: 1. increased 
binding and 2. enzymatic partnering (Figure 4.11). 
 Interestingly, we find that anchoring TM and EPCR to different endothelial 
determinants has no effect.  This result is consistent with the experiments 
described in Chapter 1, in which TM and EPCR were co-immobilized on 
polyurethane.  In those studies, EPCR was found to have an effect only when  
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Figure 4.11. Schematic model of dual targeting of s cFv/TM and scFv/EPCR 
to increase APC production  
(a) Normal function of thrombin, TM, EPCR, and PC on the endothelial cell 
membrane.  Endothelial TM binds thrombin (Factor IIa) and activates protein C.  
This process is accelerated by the key co-factor, EPCR, which optimally 
positions PC for cleavage.  APC can signal to endothelial cells while bound to 
EPCR or can bind to protein S and exert anti-coagulant effects, such as the 
cleavage of Factor Va. (b) APC generation by surface bound 390 scFv/TM fusion 
protein. TM fusion protein anchored to PECAM-1 generates APC, but is unable 
to partner with endogenous EPCR. (c) Mec13 scFv increases binding of 390 
scFv/TM to PECAM-1 via “collaborative enhancement” mechanism. Increased 
binding results in an ~2 fold increase in APC production.  (d) Dual targeting of 
390 scFv/TM and Mec13 scFv/EPCR.  The combination of enhanced binding and 
enzymatic partnering between TM and EPCR further increases APC production, 
to levels roughly equal to endogenous TM/EPCR.  
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the two recombinant proteins were kept in close proximity (< 10 nm)133, and 
not with a random, unordered distribution.  Although our experiments on 
mouse ECs do not establish a clear cutoff value, it seems likely that some 
critical distance exists, beyond which endothelial-anchored TM and EPCR are 
no longer sufficiently close to partner efficiently.  These results also support 
the notion that PECAM-anchored TM may be unable to partner with 
endogenous EPCR due to insufficient proximity along the membrane surface. 
 Apart from its mechanistic significance, dual targeting of TM and EPCR 
fusion proteins to paired PECAM-1 epitopes demonstrates enhanced protection 
in vivo and could represent a plausible strategy for mitigating acute endothelial 
dysfunction in a variety of settings. 
 
IV. MATERIALS AND METHODS 
Cell lines 
 Lysate from the Mec13.3 hybridoma (herein referred to as Mec13) was a 
generous gift of Dr. Annunciata Vecchi.  MS1 cells were purchased from ATCC 
(Manassas, VA) and maintained in DMEM with 10% FBS and 1% antibiotic-
antimycotic (Life technologies, Grand Island, NY). 
 
Antibodies and other reagents 
 Anti-TM polyclonal antibody (AF3894) was purchased from R&D systems 
(Minneapolis, MN).  A second anti-TM polyclonal antibody, used in Western 
blotting (sc-7097) was purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA).  The anti-EPCR blocking mAb 1560, was supplied by the Esmon laboratory.  
HRP-conjugated Anti-FLAG (M2-HRP) antibody was obtained from Sigma 
Aldrich (St Louis, MO).  HRP-conjugated anti-goat secondary antibody (sc-2056) 
was from Santa Cruz Biotechnology.  Purified recombinant human protein C was 
a generous gift of Dr. Sriram Krishnaswamy.  Bovine thrombin and 
lipopolysaccharide (LPS, serotype B4) were purchased from Sigma. APC 
substrate, S-2366, was purchased from Diapharma (West Chester, OH). 
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Cloning of Mec13 VL and VH cDNAs 
 Mec13.3 cell lysate in Trizol was extracted with chloroform and phases 
were separated by centrifugation.  The aqueous phase was removed, mixed with 
ethanol, and total RNA was purified using the RNeasy kit (Qiagen, Valencia, CA).  
Combined reverse transcription and PCR was performed using SuperScript One 
Step RT-PCR kit (Life Technologies, Grand Island, NY).  Mec13 light chain was 
purified on reducing SDS PAGE and sent for N-terminal (Edman) sequencing at 
the UC Davis Proteomics Core Facility.  The 7 amino acids identified were used 
to design degenerate PCR primers. 
 
Assembly and expression of Mec13 scFv, sEPCR, and Mec13/EPCR constructs 
 Completed Mec13 VL and VH cDNAs were assembled into a scFv 
construct, with VH and VL sequences separated by a (GGGGS)3 linker and a 
triple FLAG tag appended to the 3’ end (C-terminus) for purposes of purification 
and detection.  The extracellular domain of mouse EPCR (sEPCR) was cloned 
by PCR from the full-length cDNA described in Chapter 2, and a C-terminal triple 
FLAG tag appended.  Finally, the Mec13 scFv/EPCR fusion protein was 
constructed with mEPCR on the 5’ end (N-terminus), separated from the Mec13 
scFv by an (SSSSG)2AAA linker.  All proteins were expressed in S2 cells and 
purified using an anti-FLAG affinity column (Sigma Aldrich, St Louis, MO). 
 
Generation of REN-derived stable cell lines 
 REN-PECAM-TM and REN-ICAM-TM cells.  To make cells expressing 
both PECAM/TM and ICAM/TM, a mouse TM (mTM) cDNA (containing the entire 
coding sequence of mTM and a portion of the 5’ and 3’ UTRs, nt 87-3482) was 
purchased from Origene and cloned into the pcDNA3.1/Zeo(-) vector (Life 
Technologies, Grand Island, NY).  Since REN-PECAM and REN-ICAM cells 
already stably express the Geneticin resistance gene, this expression vector 
(which confers resistance to the antibiotic Zeocin) was utilized.  Each cell type 
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was transfected with Lipofectamine 2000 and selected in media with 250 µg/mL 
of Zeocin and 200 µg/mL of Geneticin. 
 
Live cell ELISA assays 
 ELISAs were performed on live cells as described in Chapters 2 and 3.  In 
ELISA experiments involving more than one recombinant protein, however, such 
as those aimed at measuring collaborative enhancement of binding, anti-FLAG-
HRP could not be used, as each fusion protein carries a C-terminal triple FLAG 
tag.  In these cases, detection was via either goat anti-mTM or goat anti-mEPCR 
polyclonal antibody, with an anti-goat-HRP secondary antibody.  ELISA binding 
data was analyzed using PRISM 6.0 software (GraphPad, San Diego, CA). 
 
Protein C ELISA 
 ELISAs were performed using the same protocol as above, except that 
instead of live cells, fusion proteins were bound to protein C immobilized on high-
binding plastic wells.  Briefly, wells were incubated overnight at 4°C with a 
solution of 4 µg/mL recombinant human protein C in Tris buffered saline (TBS).  
Protein C solution was removed and the plate was blocked with 3% BSA solution 
for 2 hours.  BSA-coated wells with no protein C were used as a control for non-
specific binding.  
 
Protein C activation assays 
 Generation of APC by scFv/TM fusion was assayed as described in 
Chapters 2 and 3.  Briefly, cell monolayers were incubated with various 
combinations of TM and EPCR fusion proteins and washed three times with 
media prior to the addition of 1nM thrombin and 100nM protein C.  In all cases, 
protein C activation occurred at 37 °C in assay buf fer (20 mM Tris, 100 mM NaCl, 
1 mM CaCl2, 0.1% (w/v) BSA, pH 7.5), and the reaction was stopped by addition 
of an excess of hirudin.  Anti-mTM antibody blockade and EPCR blockade using 
mAb 1560 were performed as described in Chapter 2. 
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IT LPS model 
 Animal studies were carried out in accordance with the Guide for the Care 
and Use of Laboratory Animals as adopted by the NIH, under protocols (803320 
and 804349) approved by University of Pennsylvania IACUC.  The IT LPS model 
was performed as described in Chapter 3, with several exceptions.  First, in 
some experiments, animals received more than one fusion protein, e.g., scFv/TM 
and scFv/EPCR.  Proteins were injected IV in rapid succession, not mixed.  
Likewise, bronchoalveolar lavage was not performed in these experiments. 
 
Data analysis and statistics 
 Results are expressed as mean ± SD unless otherwise noted. Significant 
differences between means were determined using Students t-test or one-way 
ANOVA followed by appropriate multiple comparison (Tukey) test.  P<0.05 was 
considered statistically significant. 
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CHAPTER FIVE: DISCUSSION AND FUTURE DIRECTIONS 
 
 
I. LIMITATIONS 
The body of work described here is not without limitations.  Of greatest 
concern is the issue touched upon in Chapter 1, namely that the 390 and YN1 
scFv/TM fusion proteins are constructed with the N-terminal lectin domain of TM 
adjacent to the scFv moiety (Figure 1.2b).  Although the data presented in 
subsequent chapters indicates that this “inverted” conformation does not entirely 
preclude the partnering of scFv/TM fusion proteins with endogenous surface 
partners (e.g., EPCR) or co-delivered fusion proteins (e.g., scFv/EPCR), it is 
likely to have some significant impact on the function of TM, and we have yet to 
investigate this possibility in detail.  For example, we have only examined the 
functional activity of endothelial targeted TM fusion proteins with respect to APC 
generation.  TM is well known to have numerous other functions, including the 
direct neutralization of cytokines via its N-terminal lectin domain and the 
activation of TAFI122,161.  These activities may be altered or completely absent 
given the unnatural conformation of the TM moiety in the current generation of 
fusion proteins. 
The use of MS1 cells, a transformed pancreatic-derived endothelial cell 
line, represents another significant technical limitation of the current body of 
work.  Immortalized endothelial cells are likely to differ substantially from primary 
cultures and/or ECs in vivo, in particular with regard to the precise spatial 
relationships between endothelial surface molecules.  Moreover, it is plausible 
that we have masked some of the significance of these issues via the use of 
reagents from several different species -- i.e., bovine thrombin and human PC 
zymogen, alongside mouse TM and EPCR. 
Finally, the significance of our conclusions must be tempered by the 
preliminary nature of the work.  We have yet to investigate any cytoprotective 
signaling through PAR1 or other receptors, which might be generated by 
endothelial targeted TM and EPCR fusion proteins. Since PAR1 is thought to 
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localize to the same apical membrane microdomains as EPCR96, it is possible 
that PECAM-anchored TM will demonstrate weak cytoprotective signaling 
through this receptor.  Furthermore, dual targeting of scFv/EPCR fusion protein 
to PECAM, which has a significant effect on APC generation, may have little or 
no impact on PAR1 signaling.  On the other hand, it is possible that the 
requirement for molecular proximity may be less stringent in this case, as APC 
generated by TM and/or EPCR fusion proteins might diffuse along the endothelial 
surface, bind to endogenous EPCR, and signal through PAR1 in a paracrine 
manner.  This intriguing issue clearly merits further investigation.  Likewise, 
further characterization is warranted with regards to the in vivo protection offered 
by the fusion proteins.  IT administration of LPS does not faithfully reproduce all 
of the pathological aspects of human lung injury162.  Likewise, administration of 
fusion protein prior to LPS does not reflect a realistic clinical scenario.  A rigorous 
appraisal of the benefit/risk ratio of TM and EPCR fusion proteins will need to be 
conducted in relevant animal models of human disease, with administration after 
the onset of injury.  Moreover, we will need to directly test the importance of 
TM/EPCR partnering in vivo, before definitively concluding that this factor is 
responsible for any differences we observe in the therapeutic efficacy of various 
fusion proteins. 
 
II. FUTURE DIRECTIONS 
 
Design of Human PECAM and ICAM-targeted TM Fusion P roteins 
 To simultaneously address the various technical limitations discussed 
above, we have cloned two new scFvs, Ab62163 and R6.5164, which are specific 
for human PECAM-1 and ICAM-1, respectively (Figure 5.1a,b).  We are in the 
process of assembling these into fusion proteins with human TM (hTM).  Unlike 
the previous generation of mouse specific fusion proteins, we have designed the 
scFv/hTM fusion proteins in both available conformations (Figure 5.1c), including 
a more natural configuration with the lectin domain free at the N-terminus of the 
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molecule.  This will allow us to test the significance of the “natural” vs. “inverted” 
conformations, not only on the various functions of hTM, but also its partnering 
with endogenous surface molecules.  The widespread availability of high quality 
human primary ECs (e.g., HUVECs and human pulmonary microvascular 
endothelial cells, or HPMVECs), will resolve any artifacts related to the use of 
immortalized cells.  Finally, hTM fusion proteins will be tested using human PC 
and thrombin, thus eliminating any issues related to species variation of 
reagents. 
 The use of human ECs will enable testing of signaling pathways and cell 
responses not possible with MS1 cells.  In particular, HUVECs and HPMVECs 
both form tight monolayers and can be used for testing endothelial permeability.  
Since both thrombin and APC affect endothelial barrier function through PAR184, 
we plan to use permeability assays as an important means of testing the new 
hTM fusion proteins and their capacity to influence signaling through this 
receptor.  Other responses known to depend on APC mediated signaling, e.g., 
the expression of cell-adhesion molecules, will also be examined. 
 Finally, the use of Ab62 scFv/hTM and R6.5 scFv/hTM fusion proteins 
should allow the study of other TM functions, including the potential neutralization 
of HMGB1, a damage-associated molecular pattern molecule (DAMP) and 
cytokine.  HMGB1 is bound and sequestered by the N-terminal lectin domain of 
TM and infusion of recombinant sTM has been shown to reduce its plasma 
concentration in animal models of systemic inflammation165,166.  The N-terminus 
of the lectin domain, which is exposed in both soluble and membrane-bound TM, 
may be inaccessible on the fusion proteins due to its positioning adjacent to the 
scFv moiety.  Most importantly, these new scFv/TM fusion proteins will allow pre-
clinical development in primates and, ultimately, testing in human clinical trials if 
warranted. 
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Figure 5.1. Human PECAM-1 Specific Ab62 scFv 
(a) Molecular design of Ab62 scFv, (b) Ab62 scFv binds to human PECAM-1, as 
demonstrated by live cell ELISA (done with REN cells transfected with human 
PECAM-1) and immunofluorescence of HUVECs.  Strong staining seen at cell-
cell junctions is typical for PECAM-1.  (c) Fusion of Ab62 scFv with human TM in 
both conformations, for testing of lectin and EGF domain function. 
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Strategies to Define and Improve Endothelial Target ing  
 One aspect of the endothelial targeted TM fusion proteins that remains 
poorly characterized is their ability to target the endothelium in vivo.  Although 
initial experiments indicated that 390 scFv/TM effectively targets the lung 
following intravenous injection127, subsequent efforts have failed to confirm 
thisresult.  Likewise, the biodistribution of YN1 scFv/TM, which has been more 
rigorously characterized, indicates very weak targeting to lung endothelium.  This 
result was somewhat unexpected, given the robust targeting of the parental mAb 
(Figure 5.2), and the fact that the scFv/TM fusion proteins are large enough to 
escape the rapid renal clearance seen with free scFvs. 
 There are multiple possible explanations for these findings.  First, the 
scFv/TM fusion proteins are monovalent, and the decreased avidity, as 
compared to mAbs, could have a drastic effect on their ability to anchor 
themselves to the endothelium under the flow conditions present in the 
vasculature.  Second, TM may mediate uptake or clearance of fusion proteins by 
the liver and spleen.  Third, scFv/TM fusion proteins lack Fc domains and 
therefore are incapable of recycling through the neonatal Fc receptor (FcRn), 
which markedly prolongs the circulation time of mAbs167.  Finally, there is some 
evidence that even bivalent engagement of ICAM-1 may induce internalization by 
ECs, meaning that some component of the lung biodistribution of YN1 mAb may 
reflect intracellular, rather than surface bound antibody168.  Of note, this latter 
possibility differs from the others in that it would be a potential negative for 
endothelial targeting of TM, which requires surface localization. 
 To investigate these possibilities, we are in the process of designing and 
testing several new constructs.  In particular, we are collaborating with the 
Tsourkas laboratory in the Department of Bioengineering to develop a means of 
site-specific conjugation of TM to anti-PECAM and anti-ICAM mAbs.  
Conventional mAb conjugation, which utilizes non-specific chemistry, is limited by 
poor efficiency, the possibility of impaired mAb or cargo (i.e. TM) function, and 
the inability to limit or precisely control conjugate size.  The introduction of site 
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specific modifications on the mAb and TM moieties, however, allows the use of 
highly efficient click chemistry, results in predictable orientation of the 
components, and enables the incorporation of only one mAb and TM into each 
conjugate (Figure 5.3).  Using this new technology, we plan to test the role of 
each of the above factors (avidity, TM clearance, FcRn recycling, and 
internalization) in determining biodistribution to the lung and other organs.  Better 
understanding of these variables should allow the eventual design of TM 
therapeutics with improved endothelial targeting. 
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Figure 5.2. Biodistribution of YN1 scFv/TM and YN1 mAb in vivo 
(a) Biodistribution of YN1 scFv/TM at 30 min post-injection shows weak, but 
specific targeting to the lung, based on comparison to sTM and testing in ICAM-/- 
mice.  (b) Lung targeting of YN1 scFv/TM is an order of magnitude weaker than 
parental mAb. 
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Figure 5.3. Design of site-specific mAb/sTM conjuga tes 
Conventional bioconjugation is limited by potential disruption of mAb and sTM 
function, as well as inability to control the size of the resulting conjugate.  Site-
specific conjugation, in contrast, allows 1:1 incorporation with defined orientation 
of the individual components. 
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